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Post-translational modifications (PTMs) play a crucial role in trafficking proteins for many 
location-dependent cellular functions. Protein S-acylation describes the addition of long chain 
fatty acids (predominantly the C16:0 palmitate) to cysteines via a thioester bond. This reversible 
modification thus allows for controlled regulation of protein membrane tethering during various 
cellular processes. Indeed, S-palmitoylated proteins include kinases, small GTPases and 
transmembrane receptors, which function in response to diverse signaling events. It is important 
to study the enzymes that catalyze this modification since it is involved in many essential 
pathways. Enzymes such as APT1 and APT2 have thoroughly been studied and shown to 
depalmitoylate a myriad of S-palmitoylated substrates and the development of selective 
inhibitors has accelerated the discovery of new substrates. ABHD17 has more recently been 
shown to depalmitoylate substrates in cell-based studies. However, not much is known about its 
substrate recognition mechanism and cellular function and my dissertation helps to bridge this 
gap in knowledge. The first chapter presents a detailed introduction to protein depalmitoylases, 
their different cellular roles and methods that have been developed to study them. The following 
chapter focuses on understanding the in vitro activity of ABHD17 and the development of 
potential inhibitors to study its function. The third chapter outlines a proteomics strategy that can 
be used to study S-palmitoylation of multiple proteins at a time and was applied to understand 
how ABHD17 regulates S-palmitoylation in cells. Finally, future experiments are proposed in 
Chapter 4 to further improve our understanding of how ABHD17 works and what its cellular 
function is.  
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Chapter 1 Introduction* 
 
1A. Abstract 
Protein depalmitoylation describes the removal of thioester-linked long chain fatty acids from 
cysteine residues in proteins. For many S-palmitoylated proteins, this process is promoted by 
acyl protein thioesterase enzymes, which catalyze thioester hydrolysis to solubilize and displace 
substrate proteins from membranes. The closely related enzymes acyl protein thioesterase 1 
(APT1; LYPLA1) and acyl protein thioesterase 2 (APT2; LYPLA2) were initially identified 
from biochemical assays as G protein depalmitoylases, yet later were shown to accept a number 
of S-palmitoylated protein and phospholipid substrates. Leveraging the development of isoform-
selective APT inhibitors, several studies report distinct roles for APT enzymes in growth factor 
and hormonal signaling. In addition to APT enzymes, the ABHD17 family of hydrolases 
contributes to the depalmitoylation of Ras-family GTPases and synaptic proteins. Overall, 
enzymatic depalmitoylation ensures efficient membrane targeting by balancing the 
palmitoylation cycle, and may play additional roles in signaling, growth, and cell organization. 
This chapter provides a perspective on the biochemical and cellular analysis of protein 
depalmitoylases, and outline opportunities for future studies of systems-wide analysis of protein 
depalmitoylation. 
 
* This chapter comprises sections from a peer-reviewed review article.1 My contribution to this review includes 
figures and assistance in writing.  
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1B. Introduction 
S-Palmitoylation describes the addition of a long-chain fatty acid to a cysteine residue via 
a thioester linkage.2 This hydrophobic post-translational modification promotes the membrane 
tethering, trafficking, and localization of a significant fraction of membrane-associated proteins. 
While the term “S-palmitoylation” implies exclusive modification by 16:0 fatty acids, the 
cellular profile of fatty acylated cysteine residues likely includes a variety of long chain fatty 
acids with differing unsaturation,3-5 and is interchangeably used with the term “S-acylation”. 
Protein S-palmitoylation is catalyzed by a family of protein acyl transferases, termed zDHHC 
enzymes due to their predicted Zn2+-binding and conserved Asp-His-His-Cys motif.6-8 These 
multi-pass transmembrane proteins catalyze acyl transfer from long chain fatty acyl-CoAs to 
cysteine residues in proteins. Humans express 23 zDHHC enzymes that influence many diverse 
cellular pathways. For example, zDHHC5 deletion blocks neuronal stem cell differentiation,9 and 
along with its close homologue zDHHC8, localize to synapses in neurons10 where they influence 
activity-dependent endocytic trafficking, excitability, and synaptic connectivity.11 In addition, 
zDHHC2 palmitoylates Src-family kinases,12 while inhibition of close homologue zDHHC20 
prevents EGFR S-palmitoylation and enhances the action of EGFR inhibitors.13 zDHHC9 is 
reported to S-palmitoylate Ras,14, 15 and is genetically linked to X-linked mental retardation.16 
Across dozens of publications, zDHHC enzymes have emerged as critical regulators of protein S-
palmitoylation and membrane targeting.2, 17 
Perhaps the most intriguing aspect S-palmitoylation is its reversibility, since thioester 
hydrolysis eliminates the fatty acyl anchor to modulate membrane localization and/or function. 
For example, cycles of acylation and deacylation are required for the plasma membrane 
association of Ras-family small GTPases and G proteins,18-20 establishing a distinct mode of 
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peripheral membrane protein directionality dependent on a continuous palmitoylation cycle.21, 22 
Indeed, pharmacological inhibition with promiscuous inhibitors of either zDHHC PATs or 
depalmitoylases block the plasma membrane targeting of Ras and G proteins.21, 23, 24 
Microinjection of semi-synthetic fluorescently-labeled S-palmitoylated Ras rapidly redistributes 
to the Golgi, which is established as the destination of depalmitoylated Ras.22 Based on these 
findings, peripheral membrane protein S-palmitoylation requires a balanced cycle of both 
zDHHC enzymes and depalmitoylating enzymes for efficient transport along the flux of the 
secretory pathway towards the plasma membrane.21 Furthermore, both Ras and G proteins are 
rapidly depalmitoylated in their GTP-bound state,25-27 which coincides with, but is not required 
for agonist dependent-internalization to internal membranes.24 Based on these examples, 
constitutive protein S-palmitoylation is required for proper trafficking of many peripheral 
membrane proteins, but may also function as a reversible signal analogous to protein 
phosphorylation (Figure 1-1). For example, serum, growth factor, or phorbol ester addition 
triggers deacylation of a 64 kD protein in [3H]-palmitate labeled mouse BH3C1 cells,28 which in 
light of more recent proteomics studies,29 likely corresponds to depalmitoylation of metadherin, a 
major driver of cancer and metastasis.30 Therefore, external stimuli trigger either direct activation 
of depalmitoylases, or facilitate conformational changes that enhance depalmitoylase 
accessibility, which then tips the balance of the palmitoylation cycle to reorganize membrane 
distribution and signaling outputs. 
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Figure 1-1 Cellular pathways of protein depalmitoylation. 
Protein depalmitoylation can proceed by either non-enzymatic hydrolysis, inducible depalmitoylation, or constitutive 
depalmitoylation during trafficking. zDHHC enzymes are shown as transmembrane proteins. 
 
While this model is appealing, a number of fundamental questions remain, such as 1) what 
enzymes catalyze depalmitoylation of different S-palmitoylated proteins, 2) what, if anything, 
triggers their activation, and 3) is there a coincident dysregulation of protein acyl transferase 
enzymes to block re-palmitoylation? In addition to peripheral membrane proteins, many integral 
membrane proteins such as channels, receptors, and adhesion proteins also require S-palmitoylation 
for proper activation, sensitization, or microdomain localization. Given the ever-expanding number 
of bona fide S-palmitoylated proteins,31 how broad is the role for depalmitoylases in regulating S-
palmitoylation stability? What is the scope of enzymatic depalmitoylation compared with the 
intrinsic hydrolysis of the high-energy thioester linkage? Through the development of new methods 
and model systems, these questions are central to understanding the role of dynamic S-palmitoylation 
in physiological systems. 
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1A. Palmitoyl protein thioesterase 1 
Several early reports demonstrated enhanced depalmitoylation upon hormonal 
stimulation, suggesting activation of specific depalmitoylases might regulate intracellular 
signaling pathways.26, 27, 32 For example, both Ras and G proteins are more rapidly 
depalmitoylated after activation, which was believed to contribute to more efficient 
internalization. Several candidate depalmitoylating enzymes were later identified by activity-
guided fractionation and purification from soluble tissue homogenates.33, 34 While technically 
feasible, this approach ignored the presence of any membrane-bound depalmitoylating enzymes. 
Nonetheless, the lysosomal hydrolase PPT1 was identified as the most robust H-Ras 
depalmitoylase in vitro.33 PPT1 was later found to localize exclusively in lysosomes and late 
endosomes,35 functionally separating PPT1 from depalmitoylase activity in the cytosol or on 
plasma membrane. PPT1 is one of 14 genes genetically linked to the family of human neuronal 
ceroid lipofuscinosis (NCL) lysosomal storage diseases, characterized by accumulation of 
lysosomal autofluorescent storage material, neurodegeneration, and childhood mortality.36  
Interestingly, while not localized in the lysosome, mutations in cysteine string protein alpha gene 
(CSPα) also lead to NCL.37 CSPα is multiply S-palmitoylated, and functions as a HSC70 
interacting J-protein important for protein folding and synaptic vesicle function. In CSPα mutant 
cells, PPT1 is highly over-expressed.38 Furthermore, PPT1 can depalmitoylate CSPα in vitro, 
which is reported to lead to the formation of insoluble aggregates. Acyl-RAC analysis of CSPα 
mutant cells revealed decreased S-palmitoylation of several synaptic proteins and neuronal 
signaling proteins. Overall, PPT1 is likely not contributing to plasma membrane 
depalmitoylation, but could play a role in vesicular depalmitoylation and lysosomal degradation 
of S-palmitoylated proteins.  
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1B. Acyl protein thioesterases 
The reported lysophospholipase LYPLA1 was identified by screening soluble tissue 
homogenates for G protein depalmitoylase activity,34 and subsequently renamed acyl protein 
thioesterase 1 (APT1). In addition to its depalmitoylase activity, APT1 hydrolyzes a broad 
profile of lysophospholipids and other long-chain mono-acyl glycerol esters, albeit at a lower 
catalytic efficiency than high-energy S-palmitoylated substrates.39, 40 Since APT1 was first 
reported before the development of RNAi methods, much of the first decade of depalmitoylase 
research relied on in vitro biochemistry or over-expression studies. Over-expression of APT1 
enhances the depalmitoylation of small GTPases,41, 42 endothelial nitric oxide synthase,43 and a 
number of other peripheral membrane proteins in transfected cells. Such over-expression could 
lead to a number of potential artifacts, either by disruptive fusion of epitope tags or fluorescent 
proteins, or through saturation of binding partners at non- physiological expression levels. If the 
enzyme concentration increases much beyond physiological levels, the rate of substrate 
hydrolysis will also increase, and potentially promote depalmitoylation of non-physiological 
substrates. In addition, over-expression could also impart non-physiological depalmitoylase 
activity to otherwise dedicated lipid modifying enzymes, particularly since thioesters are high 
energy bonds readily hydrolyzed by even weak nucleophiles. Over-expressing candidate S-
palmitoylated substrates is also problematic, since high expression levels can approach the 
enzyme Km, further promoting APT1-dependent depalmitoylation of non-native substrates. Even 
so, APT1 can depalmitoylate a number of proteins in cells. In fact, the neuronal microRNA 
mi138 modulates APT1 levels in synaptic spines, reportedly affecting spine volume through 
modulation of Gα13 S-palmitoylation.44 
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In addition to APT1, vertebrates express the highly similar depalmitoylase APT2, (68% 
identical, 81% similar). APT2 also hydrolyzes lysophospholipids,45 but in contrast to APT1, it 
also hydrolyzes prostaglandin glycerol esters.46 Both APT1 and APT2 act as efficient 
depalmitoylases in vitro,40 and are presumed to broadly regulate S-palmitoylation and trafficking 
of peripheral membrane proteins in cells. Unfortunately, there are no quality commercial sources 
of APT1 and APT2 antibodies, since they are likely poorly immunogenic due to nearly exact 
conservation across most mammals, including mice, rabbits, and humans. Thus, most studies on 
APT1 and APT2 localization have used GFP or epitope fusions for subcellular analysis. The 
literature consensus reveals both enzymes are primarily cytoplasmic, although partially localized 
on internal membranes,47 or in some instances on the plasma membrane.42, 48 APT1 has also been 
found to be primarily localized and active in the mitochondria, however the mechanism by which 
it gets trafficked to the mitochondria is not known since it does not have a mitochondrial 
targeting sequence.49 Both APT1 and APT2 share a cysteine at the second position immediately 
following the initiator methionine, and are reportedly both S-palmitoylated.42, 47, 50 After removal 
of the initiator methionine, if the N-terminus is not acetylated, it may readily undergo N-acyl 
transfer to form a stable amide linkage. Interestingly, APT1 S-palmitoylation has been reported 
in only one proteomics experiments using hydroxylamine switch methods, but never by alkynyl 
fatty acid labeling.31, 50 APT1 and APT2 are expressed and active across nearly all tissues,51, 52 
yet their absence in most large-scale profiling efforts suggests they may not be stoichiometrically 
S-palmitoylated. This low-level S-palmitoylation could be caused by an alternative translational 
start site (potentially Met- 6) or through auto-depalmitoylation. Nonetheless, knockdown of 
either APT1 or APT2 promotes plasma membrane association of the other APT enzyme, 
suggesting an interdependent S-palmitoylation cycle.42  
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Based on their predicted role in regulating peripheral membrane protein localization, 
peptidomimetic inhibitors of APT1 were developed that upon microinjection could mislocalize 
N-Ras away from the plasma membrane.53 Based on these studies, derivatives of the generic 
natural product lipase inhibitor tetrahydrolipstatin were identified that potently inhibited both 
APT1 and APT2.41 The β-lactone mechanism-based inhibitors Palmostatin B and the choline-
derivative Palmostatin M40 were developed as dual inhibitors of both APT enzymes. Palmostatin 
B treatment led to accumulation of N-Ras on internal membranes, as well as partial rescue of E-
Cadherin membrane localization.41 Interestingly, knockdown of APT1 was not sufficient to 
reproduce the pharmacological effects to statistical significance, demonstrating possible 
compensatory mechanisms, either by APT2 or by other unannotated depalmitoylating enzymes. 
Single cell studies revealed altered trafficking dynamics of over-expressed N-Ras fluorescent 
protein fusions and microinjection of semi-synthetic, fluorescently labeled N-Ras. Upon growth 
factor stimulation, Palmostatin B treated cells showed reduced Ras activation on the Golgi. Later 
studies demonstrated selective growth inhibition of N-Ras, but not K-Ras driven growth of 
myeloid progenitors.54 Accordingly, Palmostatin B directly modulates N-Ras localization and 
activity by disrupting the Ras palmitoylation cycle.55 
While Palmostatin B demonstrates high potency against both APTs (IC50 < 5 nM),40 
phenotypic effects typically require > 20 μM.41, 56, 57 Early studies suggested that Palmostatin 
derivatives are highly unstable in serum, requiring repeated cycles of inhibitor addition to 
maintain inactivation.44 Nevertheless, this compound has been used in numerous studies to 
profile APT1 and APT2 function. For instance, Palmostatin B addition accelerated the 
incorporation of the 17-ODYA in Lck in unstimulated T-cells.58 However, the compound failed 
to block depalmitoylation once the cells were stimulated with Fas ligand. The authors suggested 
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that there may be distinct pools of depalmitoylases once the receptors are activated. In addition, 
the neuronal RGS-binding protein R7BP accelerates the deactivation of Gi/o proteins. Inhibition 
with Palmostatin B or HDFP both redistributed R7BP from the plasma membrane to 
endomembranes, disrupted association with G protein-regulated inwardly rectifying potassium 
(GIRK) channels, and slowed GIRK channel closure.59 Importantly, knockdown of both APT1 
and APT2 had no effect on GIRK inactivation, suggesting the presence of additional 
depalmitoylated enzymes. Chronic lymphocytic leukemia (CLL) B-cells express nearly 10-fold 
more APT2 and 2-fold more APT1. Palmostatin B treatment or APT knockdown increased 
CD95-mediated apoptosis.60 Activity-based protein profiling (ABPP) studies later demonstrated 
that Palmostatin B is not exclusive for APT1/APT2, and inactivates a number of other lipid 
processing serine hydrolases with somewhat weaker potency, including ABHD6, ABHD16A, 
ABHD17A-C, PNPLA6, and FASN.61 Accordingly, Palmostatin B should be used only as a 
generic depalmitoylase inhibitor, with a clear understanding that multiple enzymes are blocked at 
concentrations required for sustainable depalmitoylase inhibition, and the biological outcomes 
may reflect polypharmacology summed across many enzymes. 
Despite these issues, Palmostatin B remains a popular tool for blocking depalmitoylase 
activity, and even attenuates depalmitoylation in vivo after intraperitoneal injection.62 The 
MC1R G-protein-coupled receptor triggers melanin production and enhances DNA repair after 
ultraviolet irradiation. Mice with red hair MC1R variants have reduced MC1R S-palmitoylation, 
weaker cAMP stimulation, and are more susceptible to developing melanoma. Remarkably, 
intraperitoneal injection of Palmostatin B (10 mg kg-1) prior to UV irradiation increased MC1R 
S-palmitoylation and clearance of DNA photoproducts while reducing tumor growth. While 
Palmostatin B is promiscuous, at this relatively low-dose, APTs are likely to be the primary 
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targets. APT inhibition also prevents melanoma tumor cell invasion by regulating the S-
palmitoylation of the polarity organizing protein MCAM.32 Wnt5a stimulation promotes APT1-
dependent depalmitoylation of MCAM, inducing asymmetric MCAM localization to promote a 
more invasive state. Taken together, APT inhibitors may be valuable prophylactics in topical 
sunscreens to prevent melanoma. Nonetheless, the APT1 and APT2 inhibitors ML348 and 
ML349 had no effect on MAPK signaling or growth across several N-Ras-dependent melanoma 
cell lines,63 demonstrating APT activity is not essential across all cancers types or stages.  
A number of more selective APT inhibitors have been developed with more drug-like properties. 
Isoform-selective inhibitors of APT1 (ML348, Ki = 280 nM) and APT2 (ML349, Ki = 120 nM) 
were identified by high throughput screening in a competitive fluorescence polarization assay.64-
66 These inhibitors share a common piperazine-amide scaffold, but diverge through additional 
modifications to impart isoform selectivity. For example, APT1 inhibitor, ML348 has piperazine 
amide adjacent to a furanyl group but APT2 inhibitor, ML349 has a thiophene conjugated to 
thiochromane 1,1-dioxide. These isoform-selective inhibitors are active in vivo following 
intraperitoneal injection, and engage their respective targets across all major tissues.66 
Furthermore, chemical proteomics analysis of biotin-conjugated ML349 confirmed largely 
selective inhibition across the proteome at low micromolar concentrations.67 Other covalent 
APT1/APT2 dual inhibitors have been reported, including the commercially available triazole 
urea ML21168, 69 and the commercially available N-hydroxyhydantoin carbamate ML378.70, 71 
ML211 is more potent, yet the higher reactivity reflects a smaller selectivity window limiting in 
vivo applications. ML378 also inhibits ABHD6 and FAAH in mouse brain homogenates, yet 
selective inhibitors to ABHD6 and FAAH can be used as anti-target controls. Based on our 
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studies, we highly recommend ML348 and ML349 as probes for exploring APT function in cells 
and model organisms (Figure 1-2).  
 
Figure 1-2 APT inhibitor selectivity index. 
All listed inhibitors are commercially available, except the promiscuous lipase inhibitor HDFP. HDFP (fluorophosphonate), 
Palmostatin B (b-lactone), ML378 (N-hydroxyhydantoin carbamate), and ML211 (triazole urea) are covalent inhibitors, although 
the covalent Palmostatin B adduct is slowly reversible. ML211 inhibits ABHD1168 and PPT1 (unpublished). ML378 inhibits 
ABHD6, FAAH, and PPT1 at higher doses.71 
Beyond their role as protein depalmitoylases, APT enzymes can also hydrolyze a variety of 
other esters and thioester metabolites.72 APT1 and APT2 were originally characterized as 
lysophospholipase enzymes,39, 45 yet later studies demonstrated enhanced catalytic efficiency towards 
acyl-thioester-linked proteins.34 Interestingly, APT2 was identified as the primary prostaglandin 
glycerol esterase, while APT1 had no significant activity.46 Both APT1 and APT2 accelerate the 
deacylation of octanoyl-ghrelin in serum, suggesting these enzymes may also be secreted from 
cells.73 Lipopolysaccharide treatment increased in APT1 serum levels, potentially through release 
from liver. Furthermore, the intracellular APT1 mRNA and protein levels were reduced after LPS 
stimulation, yet APT2 levels were unaffected. Overall, APTs likely hydrolyze a number of more 
soluble acyl-esters and thioesters, and may have broader functional roles in vivo beyond 
depalmitoylation. 
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To add spatial and temporal resolution to depalmitoylation enzymes, a series of mechanism-
based octanoyl-thioester fluorogenic probes were developed for live cell imaging.74 Approximately 
half of the probe fluorescence in HEK293T cells was blocked by ML348 or Palmostatin B, and 
APT1 siRNA knockdown reduced probe fluorescence by 25%. Interestingly, EGF stimulation 
reduced probe fluorescence by about 10% in live cells, suggesting some growth factor regulation of 
deacylase activity. While intriguing, further evidence is needed to establish if such reductions affect 
steady-state cellular S-palmitoylation levels, particularly of S-palmitoylated growth signaling 
mediators. Given the large number of candidate octanoyl-thioesterases, these probes provide a useful 
cell-based platform to explore deacylase activity in live cells, and measure contributions across 
different candidate enzymes. 
1C. ABHD17 family thioesterases 
Until recently, APT1 was recognized as the primary depalmitoylase in cells, yet mutants 
in S. cerevisiae, Drosophila, and C. elegans have no reported phenotypes. Given that APT1 was 
initially described as the primary depalmitoylase regulating N-Ras activity, this was quite 
puzzling. Cracks in this model began to appear throughout a number of publications, most 
strikingly from evidence that H-Ras depalmitoylase activity was exclusively in insoluble cell 
fraction (P100), and not with APT1 in the soluble fraction (S100).75 Later, APT1/APT2 
knockdown was shown to have no effect on R7BP depalmitoylation, while treatment with 
Palmostatin B or HDFP both blocked activity.59 This was followed by detailed activity-based 
profiling of Palmostatin B targets, and the realization that Palmostatin B is broadly reactive 
across a number of candidate depalmitoylases.61 Clearly other depalmitoylase activities beyond 
APT1/APT2 are present in cells, and likely contribute to the depalmitoylation of plasma 
membrane localized targets, including Ras. 
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In order to identify these additional depalmitoylases, Palmostatin B-targeted hydrolases 
were over-expressed and S-palmitoylation turnover was assayed using 17-ODYA pulse-chase 
methods. This led to the identification of ABHD17 enzymes as candidate N-Ras depalmitoylases 
in COS-7 cells.61 Over-expression of catalytic dead enzyme or N-terminal truncated mutants did 
not affect the N-Ras palmitoylation cycle, confirming ABHD17 enzymes are functional 
depalmitoylases in cells. ABHD17 hydrolases (ABHD17A, ABHD17B, and ABHD17C) are 
broadly expressed in all vertebrates, and harbor multiple conserved cysteines near their N-
termini (Figure 1-3A). The N-terminal cysteine rich domain is essential for both S-
palmitoylation and plasma membrane association.76 Thus, ABHD17 enzymes are themselves S-
palmitoylated, which is necessary for plasma membrane association and proximity to other S-
palmitoylated proteins (Figure 1-3B). Importantly, deletion of the N-terminal cysteine rich 
domain has no effect on ABHD17 reactivity with fluorophosphonate activity-based probes, 
suggesting the palmitoylation motif is primarily responsible for directing membrane localization 
and does not influence enzyme activity. ABHD17A over-expression shifted N-Ras localization 
from the plasma membrane to internal membranes, indicative of more rapid S-palmitoylation 
turnover. Triple ABHD17 (A-C) knockdown stabilized N-Ras 17-ODYA labeling, while 
APT1/APT2 inhibition with ML348 and ML348 had no effect. Accordingly, ABHD17 enzymes 
(but not APT1/APT2) contribute to N-Ras depalmitoylation in cells.  
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Figure 1-3 ABHD17 enzymes are palmitoylated and localize to the plasma membrane.  
(A) ABHD17A-C are S-palmitoylated in a conserved N-terminal cysteine-rich motif separate from alpha-beta hydrolase domain. 
(B) ABHD17A-GFP localization in HeLa cells demonstrates predominant plasma membrane localization. 
 
The synaptic protein PSD-95 is rapidly de-palmitoylated after depolarization. In order to 
identify the PSD-95 depalmitoylase, a panel of serine hydrolases were individually co-expressed 
with PSD-95 in 293T and COS-7 cells.56, 77 Over-expressed ABHD17 enzymes efficiently 
depalmitoylated PSD-95 in 293T, COS-7, and primary neuronal cultures, while other 
Palmostatin B targets ABHD12, ABHD13, APT1, and APT2 had only fractional reductions in 
PSD-95 S-palmitoylation (Figure 1-4). ABHD17 over-expression reduced the synaptic clusters 
of PSD-95 and AMPA receptors in neurons, while ABHD17A/ABHD17B/ABHD17C 




Figure 1-4 Homology, depalmitoylase activity, and Palmostatin B inhibition of HDFP-sensitive serine hydrolases.  
HDFP-sensitive serine hydrolases reported from mouse B-cell hybridoma cells29 are shown based on active-site anchored 
homology. Palmostatin B targets are highlighted in red.61, 78 Enzymes that reduced PSD-95 S-palmitoylation after over-
expression are labeled with a red star.56 
In addition, ABHD17 overexpression in primary neurons reduces the S-palmitoylation of 
microtubule-associated protein 6 (MAP6), causing MAP6 retention in axons and microtubule 
stability.77 Recently the international knockout mouse consortium identified ABHD17A as one 
of the top suppressors of distal cancer metastasis in mice79 suggesting it may play a role in 
immune cell activation or surveillance. Finally, the DNA binding transcription factor TEAD is 
an important interactor of the co-transcriptional activator YAP, involved in the Hippo signaling 
pathway responsible for cell proliferation.80 ABHD17A and APT2 depalmitoylate TEAD, 
thereby mediating its degradation by E3 ubiquitin ligase and response to cell contact during the 
Hippo pathway.81 
Despite this growing number of cell-based ABHD17 studies, there is no biochemical 
evidence demonstrating in vitro depalmitoylation, enzyme kinetics, substrate specificity, or other 
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functional properties of each ABHD17 enzyme. ABHD17 enzymes may hydrolyze other lipid 
substrates, particularly since their plasma membrane association delivers them in proximity to a 
number of potential substrates. A reported biochemical high throughput screen identified 
moderately potent inhibitors of an N-terminal truncated ABHD17B protein, yet these inhibitors 
failed to inhibit full-length, mammalian cell-expressed protein (National Center for 
Biotechnology Information. PubChem BioAssay Database; AID=2200). Structural studies are 
clearly necessary to understand if the N-terminal 100 amino acids before the conserved α/β-
hydrolase domain function solely as a platform for S-palmitoylation and membrane tethering, or 
if they impart additional structural features important for substrate engagement. Future efforts 
are needed to explore the substrate profile, redundancy between isoforms, and physiological 
roles for each ABHD17 enzymes. 
1D. Assays for depalmitoylation  
Protein S-palmitoylation was first reported nearly 40 years ago,82 but even the most basic 
experiments were hindered by the limitations of [3H]-palmitate labeling. The low radioactivity and 
incorporation efficiency typically required weeks to return results for a single experiment. 83 
Furthermore, assaying [3H]-palmitate incorporation requires immunoprecipitation of a single protein, 
limiting the scope of the analysis to only specific hypotheses. Nonetheless, [3H]-palmitate metabolic 
labeling is the most accepted method for studying S-palmitoylation, particularly for measuring 
stability in pulse-chase assays. In this approach, cells are labeled with [3H]-palmitate for a fixed 
amount of time, followed by washes and incubation in media supplemented with excess unlabeled 
palmitic acid.83 After immunoprecipitation and SDS-PAGE, the rate of palmitate turnover on a 
specific protein can be quantified by autoradiography. Through such analysis, the rate of protein S-
palmitoylation turnover is generally faster than the rate of protein turnover, establishing that multiple 
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S-palmitoylation and depalmitoylation events occur throughout the lifetime of an S-palmitoylated 
protein.29 Thus, different PATs and APT enzymes may function at different stages of protein 
trafficking to promote plasma membrane delivery and residency. 
The recent development of non-radioactive detection methods has rejuvenated interest in S-
palmitoylation, providing simple methods that accelerate the identification and quantitation of S-
palmitoylated proteins.76, 84 The primary method for biochemical analysis of S-palmitoylation uses 
hydroxylamine to hydrolyze all thioesters across the proteome, followed by capture of the newly 
liberated thiols.85-87 These hydroxylamine-switch methods begin with reduction of disulfides with 
tris(2-carboxyethyl)phosphine (TCEP), followed by treatment with maleimide to alkylate all reduced 
thiols. Next, neutral hydroxylamine is added to hydrolyze thioesters, which coincidentally hydrolyzes 
other mechanistic protein-linked thioesters including ubiquitin ligases and lipoamide-dependent 
dehydrogenases. Any hydroxylamine sensitive thiols are then captured using a pyridyl-disulfide 
biotin conjugate for streptavidin-resin enrichment (biotin-exchange) or captured directly with 
pyridyl-disulfide resin (Acyl-resin assisted capture; Acyl-RAC) for further analysis.88 Pyridyl-
disulfide resin capture has at least three advantages. First, it limits capture to hydroxylamine-
sensitive thioesters, and does not capture products from other ester or other functional groups. 
Second, the captured disulfide adduct is easily reversible by TCEP, allowing simple elution for gel-
based or proteomic analysis of site-specific S-palmitoylation. Finally, since these methods avoid 
metabolic labeling, primary tissues can be readily analyzed to provide a snapshot of the steady state 
levels of S-palmitoylation. Most importantly, biotin-exchange and acyl-RAC have enabled mass 
spectrometry-based discovery and analysis across hundreds of S-palmitoylated proteins, allowing 
correlated annotation of the exact sites of S-palmitoylation.88 Such large-scale profiling efforts 
provide long lists of putative S-palmitoylated proteins, which warrant additional biochemical 
validation. This is somewhat mitigated by the S-palmitoylation database SwissPalm,31 which 
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provides a searchable platform to qualify candidates across published datasets and compare data from 
distinct experimental systems, enrichment methods, and laboratories.  
The commercially available alkynyl fatty acid derivative 17-octadecynoic acid (17-ODYA) 
provides a second non-radioactive approach for detecting S-palmitoylation.76, 89, 90 After addition to 
the cell culture media, cells process the free alkynyl fatty acid to form the coenzyme A (CoA) 
conjugate, which then serves as a substrate for enzymatic transfer to endogenous sites of S-
palmitoylation. Cells collected at different time points are then lysed and conjugated by copper-
catalyzed azide alkyne cycloaddition (CuAAC) to reporter-linked azides (fluorophores or biotin) for 
gel-based or mass spectrometry analysis. Saturated incorporation typically occurs in a few hours, 
although shorter time points can probe more rapid acylation events. For mass spectrometry-based 
analysis, lysates are conjugated to biotin-azide for streptavidin enrichment, and comparative mass 
spectrometry is performed using hydroxylamine-treated or palmitic acid-treated samples as controls. 
Additional precautions are necessary to prevent thioesterase hydrolysis during sample preparation, 
including addition of generic esterase inhibitors, limited total sample processing time, and careful 
monitoring of the pH of all reagents.91 Several proteomic studies report bioorthogonal alkynyl-fatty 
acid labeling for profiling S-palmitoylation, including analyses in immune cells,9, 29, 92 epithelial 
cells,93 and protozoa.94, 95 Importantly, alkynyl-fatty acid labeling provides a natural complement to 
hydroxylamine-switch methods, establishing two distinct enrichment methods for more confident 
analysis. 
Alkynyl-fatty acid metabolic labeling has opened new opportunities for non-radioactive 
profiling of dynamic changes in S-palmitoylation. For example, Lck S-palmitoylation turnover in 
Jurkat T-cells was assayed using alkynyl-fatty acid pulse-chase methods and quantified by in-gel 
fluorescence.96 Surprisingly, Lck depalmitoylation was accelerated after treatment with the 
phosphatase inhibitor pervanadate, yet stabilized by incubation with the non-selective hydrolase 
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inhibitor methyl arachidonyl fluorophosphonate (MAFP). Thus, activated T-cells increase Lck S-
palmitoylation cycling, which is dependent on one or more MAFP-sensitive thioesterase enzymes. 
Using similar pulse-chase methods, proteome-wide S-palmitoylation dynamics were profiled by 
quantitative proteomics in a mouse B-cell line.29 Using stable isotope labeling with amino acids in 
cell culture (SILAC) methods, matched “light” and “heavy” replicates were labeled with 17-ODYA 
over a 2 hour pulse. One of the samples was then further incubated with 10-fold excess palmitic acid 
in the presence of the translation inhibitor cycloheximide. After combining the two samples together, 
the pooled lysates were conjugated to biotin-azide for enrichment and quantitative proteomic 
analysis. While most S-palmitoylated proteins cycled palmitate at a uniform rate in the pulse-chase 
assay, a subset of proteins demonstrated accelerated turnover, including G proteins, Ras-family 
GTPases, and a number of cell polarity proteins. Furthermore, treatment with the non-selective lipase 
inhibitor hexadecylfluorophosphonate (HDFP) stabilized the same subset of dynamically S-
palmitoylated proteins, confirming direct enzymatic contribution to S-palmitoylation dynamics on 
key signaling and polarity scaffolding proteins. Based on these results, the majority of S-
palmitoylated proteins undergo basal hydrolysis, while a small subset of S-palmitoylated proteins are 
rapidly depalmitoylated by HDFP-sensitive lipases. 
Alkynyl fatty acid labeling has several inherent limitations, primarily the direct incorporation 
of the labeled fatty acid across a variety of phospholipids. Longer incubation times lead to more 
extensive alkynyl-fatty acid incorporation into phospholipid pools,97 reducing the effectiveness of 
any later chase with free palmitate. This pulse-chase suppression potentially excludes a number of 
proteins from dynamic analyses. Furthermore, addition of palmitate has major effects on cellular 
metabolism. For instance, addition of 500 μM palmitate to human primary melanocytes expressing 
the variants of the melanocortin 1 receptor (MC1R) increased cAMP levels by almost 3-fold, 
potentially through direct enhancement of GPCR S-palmitoylation.62 Exogenous fatty acids also 
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increase cellular acyl-CoA levels,5 which may enhance S-palmitoylation levels by driving zDHHC 
activity or by non-enzymatic thioester exchange with accessible cysteine residues. For example, 17-
ODYA in the presence of 2- bromopalmitate (a non-selective palmitoylation inhibitor) only partially 
reduces incorporation of the 17-ODYA.98 Therefore, non-enzymatic palmitoylation levels may be 
enhanced by 17-ODYA incubation, elevating acyl-CoA pools to driving non-physiological thioester 
exchange to enhance levels of S-acylation. 
Another major caveat is metabolic labeling can only occur at accessible, reduced cysteines. 
Thus, stable S-palmitoylated cysteines are essentially invisible, since they do not turnover to present 
a free thiol substrate for zDHHC PAT enzymes. Accordingly, the more stable S-palmitoylation site, 
the more challenging it is to assay by metabolic labeling. In addition, high palmitate levels can 
induce oxidative stress,99 which may trap depalmitoylated thiols as oxidized disulfides or glutathione 
adducts. Different zDHHC enzymes have also been shown to prefer different fatty acyl-CoAs,5 
suggesting an additional level of diversity that could select against a single alkynyl fatty acid species 
to bias probe incorporation. Varying the acyl length of the alkynyl reporter revealed different acyl 
preferences, particularly since terminal azide conjugates surprisingly have little influence on zDHHC 
acyl specificity.5 Moreover, any differential turnover rates between distinct sites in the same protein 
are effectively averaged in shotgun proteomics experiments, since there are no robust mass 
spectrometry methods to broadly profile fatty S-acylated peptides. [3H]-palmitate can be elongated or 
shortened by ß-oxidation, further diversifying the labeled acyl species. This is particularly 
problematic when 17-ODYA is shortened to 15-pentadecynoic acid, which is enzymatically 
incorporated into N-myristoylation sites.76, 84 Despite these pitfalls, metabolic labeling remains the 
most common approach to profile S-palmitoylation dynamics, on select proteins or across the 
proteome. 
 21 
These enrichment strategies for S-acylated proteins can be coupled with mass 
spectrometry-based approaches for large scale analysis of whole proteomes. Mass spectrometry 
allows for the separation and detection of ions by mass to charge (m/z) ratio, which can be used 
to measure the amount of a molecule of interest. This works well for samples of low complexity 
such as purified proteins, which can be sequenced by mass spectrometry.100, 101 However, when 
analyzing cell extracts containing thousands of proteins, an additional separation method is 
necessary to prevent overlapping signals which complicate the quantification and identification 
of individual proteins. Thus, liquid chromatography is a compatible technique that is often added 
in-line prior to mass spectrometry.102 ‘Bottom-up’ proteomics is commonly used to identify and 
measure proteins from a complex cell extract.103 Proteins can be digested into smaller peptides 
using proteolytic enzymes such as trypsin and first separated by liquid chromatography based on 
their size and hydrophobicity. Then the peptides are ionized by electrospray ionization and 
introduced into the mass spectrometry so that their mass to charge ratios can be measured. The 
peptides can be further fragmented to generate ions used to map the amino acid sequence of the 
original peptide.104 The protein sequences from specific organisms can be obtained from public 
databases such as Uniprot.105 These sequences can be digested in silico and the resulting peptides 
can be fragmented to generate theoretical fragment spectra, which can be compared to the 
experimental spectra. Thus, the identity of the proteins can be inferred based on the list of 
identified peptides.106, 107 
1E. Overview of thesis 
Cycles of S-palmitoylation and depalmitoylation provide a mechanism for membrane 
sampling and trafficking of peripheral membrane proteins to the plasma membrane.21 Such 
directional palmitoylation cycles are demonstrated for G proteins, Ras, Scrib, and other central 
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regulators of cell growth and organization. G protein internalization occurs even in the presence 
of generic depalmitoylation inhibitors, demonstrating that while depalmitoylation may be 
necessary for plasma membrane trafficking, agonist-dependent internalization occurs 
independent of depalmitoylation.24 Based on these findings, many peripheral membrane proteins 
require cycles of S-palmitoylation and depalmitoylation for plasma membrane delivery, but there 
are no definitive examples of post-translational regulation of depalmitoylation activity. Rather, 
depalmitoylation appears to depend more on sub-cellular localization and regulated expression. 
ABHD17 enzymes localize to the plasma membrane, where they have direct access to neuronal 
scaffolding proteins and growth regulators. APT enzymes are soluble, and cytoplasmic or in the 
mitochondria, and play active roles in maintaining the directional palmitoylation cycle important 
for peripheral membrane protein trafficking. 
With the emergence of novel depalmitoylating enzymes, it is important to annotate the 
substrate profile and functional regulation by each enzyme. Chapter 2 outlines the biochemical 
characterization of ABHD17 in an effort to understand its function. We found that ABHD17 
isoforms are palmitoylated by a similar subset of DHHC enzymes, suggesting that they do not 
undergo different processing pathways as they get trafficked to the plasma membrane. After 
comparing the rate of ABHD17 enzyme, purified from E.coli and HEK293T cells, we also 
demonstrated that S-palmitoylation does not impact the enzyme activity. While Palmostatin B 
and HDFP are useful generic inhibitors of depalmitoylases, we tested and validated a compound 
that inhibits the in vitro activity of recombinant ABHD17 enzymes. Future efforts to understand 
regulation of depalmitoylation will continue to leverage emerging chemical and genetic 
technologies. In chapter 3, we applied an acyl-RAC proteomics approach to profile sites of S-
palmitoylation. Using our workflow, we obtained results similar to previously-published studies in 
addition to finding new putative palmitoylation sites on proteins. To annotate the substrates of 
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ABHD17A, we overexpressed the active and inactive forms of the enzyme in mouse embryonic 
fibroblasts that express NRAS. However, our proteomics and gel-based results showed that there 
were no significant changes in S-palmitoylation between the two treatments, hinting that ABHD17 
may influence palmitate turnover through a different mechanism. Nevertheless, we have 
demonstrated that our method allows for the large-scale identification of sites of S-palmitoylation and 
can be a valuable tool to expedite the study of other enzymes involved in the S-acylation cycle, such 
as DHHC palmitoyltransferases.
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Chapter 2 Biochemical Studies of ABHD17# 
 
2A. Abstract 
S-palmitoylation is a dynamic post-translational modification that facilitates the trafficking and 
function of many membrane proteins. This process is regulated by DHHC enzymes, which 
usually attach a 16-carbon fatty acyl group to specific cysteines. The reverse reaction is 
catalyzed by depalmitoylases, including APT1, APT2 and ABHD17 enzymes. ABHD17 has 
three main isoforms (A, B and C) that are all S-palmitoylated. Cell-based studies have shown 
that ABHD17 depalmitoylates NRAS and PSD-95, which are involved during cancer and 
synaptic development, respectively. This motivated us to determine whether these enzymes are 
functionally redundant, characterize the in vitro activity, and develop inhibitors to target them. 
Our results show that ABHD17 isoforms are palmitoylated by a similar subset of DHHC 
enzymes, suggesting a uniform processing pathway for all isoforms. ABHD17 did not accept 
palmitoylated substrates in our in vitro assay, implying that its substrate preference may not be 
palmitate. Finally, we found some compounds that inhibited the in vitro activity of recombinant 
ABHD17A and 17B, but further probe development is needed to improve compound potency 
and isoform specificity. This study has contributed to the understanding of the function of 
ABHD17 enzymes and the identification of inhibitors that can be further developed as chemical 
tools.  
 
# This chapter includes contribution from Timothy Precord (cloning, expression and purification of ABHD17 
enzymes in E.coli). APT1 and APT2 proteins were purified by Sang Joon Won and Melanie S. Cheung See Kit 
performed the remaining experiments.  
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2B. Background 
Post-translational modifications (PTMs) play a crucial role in protein trafficking for 
many location-dependent cellular functions.108 Some PTMs are mediated via stable linkages; for 
example, N-palmitoylation and myristoylation,109 while dynamic turnover happens to other 
PTMs, as is the case in S-palmitoylation, where a palmitate group gets attached to a cysteine via 
a reversible thioester linkage. S-acylation and S-palmitoylation are often used interchangeably 
since palmitate is the predominant long-chain fatty acid. This is regulated by two families of 
enzymes, namely the DHHC enzymes which acylate their substrates and the depalmitoylase 
enzymes which remove the acyl groups. Through PTM regulation, protein complexes can locate 
at the plasma membrane to regulate many cellular processes, including the control of cell 
polarity to establish cell-cell junctions for proper growth.110  
The ABHD17 enzymes are part of a larger superfamily of serine hydrolases51 and have 
been shown to be palmitoylated at the N-terminal region, which promotes their membrane 
association.76 Interestingly, there are seven ABHD17 family members (A1-A3, A5, A6, B1 and 
C1) expressed in humans compared to three mouse orthologs (A, B, and C) and all the isoforms 
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share a ~ 73 % protein sequence identity and conserved cysteine-rich N terminal region (Figure 
2-1). It is unknown whether the different isoforms have distinct functions or are redundant. 
 
Figure 2-1 Sequence alignment of the N-terminus region of ABHD17 human and mouse isoforms. 
ABHD17 exists as different human and mouse isoforms and have multiple conserved cysteines.  
 
When overexpressed, ABHD17A is reported to depalmitoylate and mislocalize NRAS.61 
ABHD17 also depalmitoylates PSD-95, a scaffold protein involved in synapse development and 
function56 as well as the microtubule-associated protein 6 (MAP6), causing MAP6 retention in 
axons and microtubule stability.77 In addition, a recent genome-wide CRISPR screen in AML 
cell lines identified ABHD17B as an essential gene in NRAS dependent THP-1 cells and NRas-
dependent Ba/F3 cells111 and the International Mouse Phenotyping Consortium (IMPC) 
identified ABHD17A as one of the top suppressors of distal cancer metastasis in mice,79 
suggesting it may play a role in immune cell activation or surveillance. Finally, the DNA binding 
transcription factor TEAD is an important interactor of the co-transcriptional activator YAP, 
involved in the Hippo signaling pathway which is responsible for cell proliferation.80 ABHD17A 
and APT2 depalmitoylate TEAD, thereby mediating its degradation by E3 ubiquitin ligase and 
response to cell contact during the Hippo pathway.81 These studies all use cell-based methods to 
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demonstrate depalmitoylation of ABHD17 substrates; however there is no current biochemical 
data for  their enzyme kinetics, substrate specificity, or other functional properties.  
Considering that PTMs play a critical role in dictating RAS subcellular localization,112 
palmitoylation has been shown to mediate RAS function as an effector of growth signaling 
pathways,113, 114 which become misregulated and trigger cancerous phenotypes.115 With genetic 
data also suggesting a role for ABHD17 in cancer, it would be valuable to develop inhibitors for 
these enzymes. The non-selective lipase inhibitor hexadecylfluorophosphonate (HDFP) targets a 
small subset of serine hydrolases, including APTs and ABHD17s.116 A high-throughput small 
molecule screening against ABHD17B has been carried out previously through the NIH 
Molecular Libraries program, resulting in the identification of putative inhibitors active against a 
truncated ABHD17 recombinant protein missing the first 20 amino acids117 and full-length 
ABHD17B in a background of mouse brain membrane proteome.118 This generated a promising 
series of oxazinones that likely inhibit through a covalent mechanism; but these compounds 
failed to inhibit the full-length ABHD17B protein. Since then, there has not been a drive to 
further validate and develop the other inhibitor chemotypes that were identified in those screens. 
We decided to follow up on some of the other lead scaffolds and take similar approaches, to ones 
previously used for APT1 and APT2, to assess the activity of the compounds. 
Fluorophosphonate-rhodamine (FP-TAMRA) is a fluorescent probe commonly used in activity-
based protein profiling (ABPP) strategies51 and can be used measure the activity of purified 
ABHD17s upon inhibitor treatment. We also previously used the fluorogenic substrate resorufin 
acetate (ResOAc) in steady-state kinetic assays to test inhibitors of APT enzymes and point 
mutations that would be detrimental to enzyme activity.119 
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Here we show that the multiple isoforms of ABHD17 are S-palmitoylated by a similar 
subset of DHHC enzymes. ABHD17 did not show depalmitoylase activity in our in vitro assay, 
implying that its substrate preference may not be palmitate. We validated some compounds that 
inhibited the in vitro activity of full length recombinant ABHD17A and 17B but further probe 
development is needed to improve compound potency and isoform specificity.  
2C. Results and discussion 
2CI. S-palmitoylation across ABHD17 isoforms is regulated by a similar subset of 
DHHC enzymes 
Since ABHD17 is expressed as multiple mouse isoforms, we compared them (17A, B, 
and C) to determine how if they had different cellular roles. Steady-state S-palmitoylation can be 
assayed using different methods, including acyl-resin assisted capture (Acyl-RAC),88 acyl biotin 
exchange (ABE)120, and acyl-PEGyl exchange gel shift (APEGS).121 These rely on the 
biochemical exchange of the acyl groups on cysteines with different probes for enrichment 
strategies (Acyl-RAC and ABE) or defined mass tags (APEGS). The APEGS assay has been 
used to quantify the in vitro palmitoylation stoichiometry of PSD-95, HRAS,56 and DHHC6.52 
Using a similar strategy, we demonstrated that ABHD17A and 17C expressed in mammalian 
cells have three sites of palmitoylation. ABHD17B did not display any mass shift, despite 




Figure 2-2 APEGS assay shows multiple S-palmitoylation sites for ABHD17 expressed in HEK-293T. 
ABHD17A and C both have three sites of S-palmitoylation. There were no observed mass shift for ABHD17B despite published 




Figure 2-3 ABHD17A is still S-palmitoylated after protein purification. 
The alkyne fatty acid is incorporated by ABHD17A and reacts to TAMRA-azide (= TAMRA-N3) after protein purification, 
indicating that the protein is still modified.  
 
To identify the DHHC enzymes that modify ABHD17, we co-expressed each ABHD17 
isoform with a panel of the mouse DHHCs in HEK-293T and used a metabolic labeling approach 
with the alkyne fatty acid mimic 17-ODYA, which gets incorporated at sites of S-palmitoylation. 
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The amount of S-palmitoylated protein can then be measured by in-gel fluorescence using a 
clickable fluorophore such as TAMRA-azide.  
 
Figure 2-4 Co-expression of ABHD17 with the full panel of 23 DHHC enzymes. 
ABHD17 isoforms were co-expressed with DHHC enzymes to measure S-palmitoylation via 17-ODYA labeling (TAMRA-N3 = 
TAMRA-azide) and normalized to protein abundance (AF647 signal). ATPase and Actin blots are included to confirm uniform 
sample loading. Gel images and bar graphs to visualize palmitoylation ratio of the ABHD17 isoform with respect to distinct 




Figure 2-5 Representative HA blot to verify DHHC expression. 
DHHC was expressed with a C-terminus 3xHA tag, which was detected with an HA antibody, which was conjugated to an 
horseradish peroxidase secondary antibody. DHHCs have different expression efficiency.  
 
Based on the data obtained after co-expression of all 23 DHHC enzymes (Figure 2-4, 
Figure 2-5), we decided to focus on a subset of DHHCs (DHHC2, 3, 5, 7, 8, 10, 15 and 21), 
which caused the largest changes in palmitoylation (Figure 2-6). For ABHD17A, DHHC2 and 
DHHC3 resulted in the largest changes. ABHD17B was mostly palmitoylated by DHHC7 while 
ABHD17C was palmitoylated the most by DHHC3 and DHHC7. Thus, there did not seem to be 
drastic differences across the DHHC enzymes that acylate ABHD17 isoforms. Since DHHC3 
and 7 are localized at the Golgi and DHHC2 is found both at the ER and Golgi,122 this suggests 
that the processing pathway for ABHD17 to traffic to the plasma membrane is the same. The 
DHHS enzyme mutants (cysteine to serine mutation), which cannot palmitoylate substrates, 
should be co-expressed with ABHD17 isoforms to further validate this finding.  
Interestingly, expression of certain DHHCs disrupted protein stability, which has been 
previously observed for other proteins such as Fas (CD95), a death receptor belonging to the 
superfamily of tumor necrosis factor receptors (TNFRs) involved in cell death,123 and TEM8 
(ANTXR1), a transmembrane protein that can be used as a receptor for anthrax toxin to enter the 
cell.124 These two proteins illustrate the interplay between palmitoylation and ubiquitination, 
which then targets proteins to lysosomes for degradation. Additional experiments are needed to 
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confirm this for ABHD17 such as: (1) labeling ABHD17 WT and palmitoylation-deficient 
cysteine mutants with [35S]cysteine/methionine pulse-chase studies to monitor protein turnover 
or (2) inhibiting the lysosomal degradation pathway to see if that rescues expression of 
palmitoylation-deficient ABHD17. After confirming the multiple sites of palmitoylation for 
ABHD17 and finding the DHHCs that modify them, we further looked into their function by 
performing different in vitro activity assays.  
 
Figure 2-6 Co-expression of select DHHC and ABHD17 isoforms. 
ABHD17 isoforms were co-expressed with DHHC enzymes to measure S-palmitoylation via 17-ODYA labeling (TAMRA-
azide) and normalized to protein abundance (AF647 signal). HRP blots are included to confirm expression of DHHCs. Gel 
images to visualize palmitoylation of ABHD17 isoform with respect to overexpression of distinct DHHCs. 2BP = 2-
bromopalmitate (non-specific inhibitor of DHHC); EV = empty vector; HRP = Horseradish peroxidase.  
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2CII. Protein expression and purification in different systems for use in functional 
activity assays 
Recombinant ABHD17A and 17B (both wildtype and catalytically inactive Ser to Ala mutant) 
were produced from E.coli to test the enzymatic activity. An initial attempt to express and purify 
the protein with an N-terminus 6xHis tag resulted in low yield (Figure 2-7A). We made 
ABHD17 constructs with three fusion tags (MBP, GB1 and Mocr) that could help improve 
expression and solubility. Maltose-binding protein (MBP) has been shown to improve protein 
solubility and provides an additional enrichment option due to its affinity for amylose resin.125 
The immunoglobulin-binding domain of streptococcal protein G (GB1) has also been used as a 
fusion strategy owing to its small size, stability and ability for high expression in bacteria.126 
Finally, the bacteriophage T7 0.3 protein (named Ocr for its ability to ‘overcome classical 
restrictions’) can be expressed as its monomeric form, hence the name Mocr, and can be 
tolerated at high levels by the cell. It has been shown to improve protein solubility and yield, 
comparable to MBP.127 MBP and GB1 both showed improved expression relative to the 6xHis 
tag alone (Figure 2-7B-C) while Mocr fusion protein did not express (not shown).  
 
Figure 2-7 Coomassie-stained SDS-PAGE gels showing the affinity purification of ABHD17B WT fused to different N-terminal 
tags. 
(A) With a 6xHis tag, ABHD17B WT is expressed at moderate level. (B) Adding an MBP domain (~42.5 kDa) improves the 
protein yield. (C) The GB1 domain (~6.2 kDa) also increases the protein expression but some remains in the insoluble fraction. 
E1 to E5 = Elution 1 to 5 
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With many non-specific contaminants eluting with the MBP fusion protein, we decided to take 
advantage of the MBP tag and add a second step of affinity purification, to then elute ABHD17B 
WT after a TEV digest. However, we were not able to fully separate the fusion protein from 
ABHD17B WT alone (data not shown). Since 6xHis-GB1-ABHD17B WT provided reasonable 
yield of protein that was active (Figure 2-8), it was used for our functional assays. 
 
Figure 2-8 Purified ABHD17A and 17B have an active Ser labeled using FP-TAMRA. 
Detection of active (A) ABHD17A WT (~ 42.8 kDa) and (B) 17B WT (~ 41.0 kDa) by FP-TAMRA in-gel fluorescence imaging 
at excitation wavelength = 532 nm and emission wavelength = 560 nm. 
 
ABHD17 is S-palmitoylated at the N-terminus76 (Figure 2-2, Figure 2-3) and we also 
purified recombinant enzyme from HEK-293T to determine whether the enzyme needed to be 
post-translationally modified in order to be recognize its substrate. In this case, we expressed an 
ABHD17 protein with a FLAG6xHis tag at the C-terminus. The FLAG purification (Figure 2-9) 
is cleaner compared to the 6xHis tag (Co resin) since FP-TAMRA labels only ABHD17 in eluted 
samples for the FLAG purification compared to the Co resin purification (Figure 2-10).  
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Figure 2-9 FLAG purification of ABHD17A expressed in HEK-293T 
Purified ABHD17A is active and labeled by FP-TAMRA. Elution 3 shows that FLAG peptide does not elute all of the protein 
bound to the FLAG beads.  
 
 
Figure 2-10 Cobalt resin purification of ABHD17A and 17B expressed in mammalian cells. 
(A) Purification of ABHD17A, where top gel shows that the protein is active and is labeled with FP-TAMRA and bottom gel is 
the Coomassie stained gel. (B) ABHD17B is also active and is labeled by FP-TAMRA; however it expresses less than 17A. 
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We then compared the rate of FP-TAMRA labeling between ABHD17 purified from 
E.coli and from HEK-293T where it is S-palmitoylated (Figure 2-11). Similar rates of labeling 
were observed, confirming past results76 where deletion of the N-terminal cysteine-rich domain 
has no effect on ABHD17 reactivity with fluorophosphonate activity-based probes. This suggests 
the palmitoylation motif is primarily responsible for trafficking to the plasma membrane and 
does not influence enzyme activity. 
 
Figure 2-11 Comparison of FP-TAMRA labeling between the unmodified and S-palmitoylated ABHD17 
FP-TAMRA labeling between the unmodified ABHD17 expressed in E.coli (A) and S-palmitoylated enzyme expressed in HEK-
293T (B) show no significant differences, as displayed in this plot (C). 
  
We also developed an in vitro assay to assess whether S-palmitoylated proteins can be 
depalmitoylated by ABHD17. Purifying NRAS labeled with 17-ODYA from HEK-293T (Figure 
2-12) provided a palmitoylated substrate to test in our assay. However, our assay did not result in 
any reduction in 17-ODYA labeling of NRAS after incubation with depalmitoylases such as 
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APT1, APT2 and ABHD17A while treatment with hydroxylamine, which chemically cleaves 
thioester bonds, showed a decrease in signal (Figure 2-13).  
 
Figure 2-12 Purification of 6xHis-Halotag NRAS protein. 
NRAS expressed with an N-terminus 6xHis-Halotag was purified using Halotag beads and reacted with TAMRA-azide to show 
that purified enzyme is still acylated (labeled with 17-ODYA).  
 
 
Figure 2-13 In vitro experiments with NRAS expressed in HEK-293T and labeled with 17-ODYA. 
Development of in vitro assay to assess NRAS depalmitoylation by ABHD17A, APT1 and APT2, measured using signal from 
17-ODYA labeled protein. Addition of hydroxylamine (NH2OH) causes cleavage of the thioester bond, unlike the incubation 
with different depalmitoylases.  
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We also tried a different approach by using Acyl-RAC where the acyl group is cleaved 
using hydroxylamine and the newly-freed thiol is alkylated with a fluorophore. Again ABHD17 
did not show any in vitro depalmitoylase activity (Figure 2-14).  
 
Figure 2-14 Alternate in vitro depalmitoylation assay strategy using a Cys alkylator conjugated to a fluorophore. 
Iodoacetamide-TAMRA (IAM-TAMRA) reacts with NRAS that is palmitoylated. No change in signal is observed. 
 
It may be that our assays are not sensitive enough to detect the changes in S-
palmitoylation and that other methods, such as mass spectrometry, must be used to quantify the 
amount of protein still modified. We also did not test lipid substrates with other acyl chain 
lengths to demonstrate that ABHD17 have a certain lipid preference. Alternatively, it is possible 
that once ABHD17 is at the plasma membrane, it undergoes structural changes required for 
substrate recognition. Another potential explanation could be that ABHD17 regulates local 
availability of palmitoyl-CoA instead, which would be consistent with the cell-based results that 
have been published before.56, 61 Therefore, further experiments are still needed to validate the 
substrate specificity of ABHD17 and elucidate its cellular function. 
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2CIII. Validation of inhibitors for full-length recombinant enzymes 
Resorufin acetate (ResOAc) has often been used as an esterase substrate since its 
hydrolysis product can be measured at a different wavelength (Figure 2-15).128 Recombinant 
GB1-ABHD17A and 17B enzymes were used to carry out steady-state kinetic assays with the 
fluorogenic ResOAc to assess the effect of different compounds selected from past screens 
(structures shown in Figure 2-15).118  
 
Figure 2-15 Overview of fluorogenic assay used to assess candidate inhibitors 
Recombinant enzymes, either WT or catalytic dead (SA), can be pre-incubated with a compound and then reacted with ResOAc 
to measure hydrolysis rates in a 96-wells format. Compounds A through G were chosen for their different scaffolds.  
 
For the steady-state kinetic assays with ResOAc, data for compound E was not included 
since the compound interfered with the signal generated by hydrolysis product. Km value 
increases in presence of inhibitors, indicating that they are disrupting the binding affinity of the 
ResOAc substrate. Treatment with the benzoxazinone derivatives (compounds A and B) resulted 
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in a higher Km value compared to the DMSO control and compound A showed equivalent 
potency towards ABHD17A and 17B isoforms (Figure 2-16). Substituted benzoxazin-4-ones 
have been previously characterized as potent irreversible inhibitors of serine proteases such as 
chymotrypsin.129 The mechanism of inhibition involves a nucleophilic reaction between the 
active site serine and the carbonyl group to form a stable acyl enzyme intermediate (Figure 
2-17).130  
 
Figure 2-16 ABHD17A and 17B are inhibited the most by oxazinone-derivative compound A. 
(A) Steady-state ResOAc hydrolysis rates for ABHD17A and 17B treated with different compounds. (B) Inhibition of 
ABHD17A and 17B by compound A. 
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Figure 2-17 Mechanism of inactivation by benzoxazinone derivatives. 
Figure was reprinted (adapted) with permission.130 Copyright (2019) American Chemical Society.   
 
In addition, we overexpressed ABHD17-GFP in HEK-293T and treated the membrane 
fraction with different compounds. This corroborated the results from the steady-state kinetic 
assays, showing that compounds A and B were effective against ABHD17A and 17B expressed 
in cells (Figure 2-18, Figure 2-19). Interestingly, compound E also decreased the FP-TAMRA 
labeling of the enzymes. As a positive control, the fractionated lysate was also treated with 
Palmostatin B (palmB), which is a non-specific depalmitoylase inhibitor.41 The other serine 
hydrolases that react with FP-TAMRA do not seem to be targeted by the compounds used since 
the other labeled bands do not appear to decrease in intensity. Finally, we treated HAP1 cells 
with compound A and used 17-ODYA metabolic labeling to look at the effect on the S-
palmitoylated proteins across the cells. However, we observed no significant changes in the 
palmitoylation levels with inhibitor treatment (Figure 2-20). Therefore, further development of 




Figure 2-18 ABPP gel with ABHD17A and 17B overexpression 
Treatment of Membrane fractions expressing (A) ABHD17A-GFP or (B)17B-GFP with 20 μM compound resulted in the 
decrease of FP-TAMRA labeling for compounds A, B and E. PalmB is a non-specific inhibitor of depalmitoylases, which serves 
as a positive control.  
 
 
Figure 2-19 In vitro treatment of membrane fraction of HEK-293T lysate overexpressing ABHD17A and 17B with FLAG6xHis 
tag. 
Inhibitor treatment was repeated using HEK-293T expressing a different ABHD17 fusion protein (FLAG6xHis tag) and results 
are similar to GFP tagged ABHD17. 
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Figure 2-20 Metabolic labeling of HAP1 cells treated with compound A or DMSO. 
(A) Metabolic labeling with 17-ODYA and click chemistry with a fluorophore (TAMRA-azide) to visualize S-palmitoylated 
proteins. (B) Compound A does not cause any major change in palmitoylation across HAP1 proteome, suggesting that the 
inhibitor does not  work well in vivo. 
 
2D. Conclusion 
Our results confirmed multiple sites of S-fatty acylation across the ABHD17 isoforms by 
APEGS assay. We co-expressed DHHC enzymes and ABHD17 isoforms and analyzed the level 
of ABHD17 palmitoylation, by 17-ODYA labeling and conjugation to a fluorophore-azide, 
showing that a similar subset of DHHC enzymes acylate ABHD17. The overexpression of 
particular DHHCs increased the degradation of ABHD17, implying that S-palmitoylation may 
play a role in its stability. Moreover, we expressed and purified ABHD17A from E.coli and 
HEK-293T to study the in vitro properties of ABHD17. FP-TAMRA labeling was used to 
measure the activity of the enzyme and the rate of labeling between the non-modified and S-
palmitoylated recombinant enzymes was comparable. Our assays showed that ABHD17 did not 
depalmitoylate recombinant NRAS protein labeled with 17-ODYA, although additional work is 
required to verify the lipid substrate preference of the enzymes. Finally, we tested potential 
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inhibitors of the recombinant enzymes in vitro, though further work is needed to develop the 
potency and isoform selectivity of the compounds.  
2E. Experimental 
Cell culture and transfection 
Human HEK-293T cells were cultured in Dulbecco’s Modified Eagle Media (DMEM; 
Invitrogen) supplemented with 1 % (v / v) 10000 Units / mL penicillin-streptomycin 
(Invitrogen), 4.5 g / L D-Glucose, 2 mM L-Glutamine, 110 mg / L sodium pyruvate, and 10 % (v 
/ v) fetal bovine serum (GE Healthcare Life Sciences). Cells were transfected using Fugene HD 
(Promega) and Opti-MEM (reduced serum media; ThermoFisher) per the manufacturer’s 
instructions and grown 2 additional days to reach confluency before being washed and collected 
for future use.  
Acyl-PEGyl exchange gel shift (APEGS) assay 
Cells were resuspended and lysed in 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 2 % 
SDS buffer and protein concentration was quantified using DC protein assay (BioRad). 1 mg/mL 
protein was diluted into buffer containing 6 M urea before incubation with 10 mM tris(2-
carboxyethyl)phosphine (TCEP; Sigma) for 30 minutes at room temperature (cysteine reduction 
step) and 50 mM iodoacetamide (IAM; Sigma) for one hour in the dark at room temperature 
(alkylation step). After chloroform/methanol precipitation to remove excess TCEP and IAM, 
protein was resuspended in 50 mM HEPES pH 7.4, 4% SDS and 5 mM EDTA buffer and mixed 
with a buffer containing 50 mM HEPES pH 7.4, 1%SDS, 5 mM EDTA, 1 M NH2OH, pH 7.4) 
for one hour at 37 °C to cleave the palmitoylation thioester bonds. As a negative control, buffer 
not containing hydroxylamine (NH2OH) was used. After a second chloroform-methanol 
precipitation step, protein was resuspended in 50 mM HEPES pH 7.4, 4% SDS buffer and 
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PEGylated with 20 mM 5k-mPEGs (Sigma) for 1 hr at RT to label newly exposed cysteinyl 
thiols. As a negative control, 20 mM NEM was used instead of mPEG (-PEG). Protein was 
precipitated again by chloroform-methanol and resuspended in SDS-loading buffer. Samples 
were heated at 95 °C for 5 minutes before being resolved by 12 % SDS-PAGE gels (180 V; 75 
minutes) and analyzed by western blot as described later. 
17-ODYA labeling across ABHD17 and DHHC co-expression panel studies  
Cells were cultured and transfected as described previously. In addition, they were treated with 
20 μM 17-Octadecynoic acid (17-ODYA; Cayman Chemicals) 16 hours prior to being washed in 
DPBS (Dulbecco's phosphate-buffered saline; Gibco) and frozen until further use.29 131 Plasmids 
expressing mouse DHHC genes tagged with 3xHA were a gift from Paul Jenkins lab (University 
of Michigan) and those expressing mouse ABHD17-GFP fusion proteins were from a previous 
paper. 76 Cells were resuspended in DPBS buffer and lysed by sonication. For in-gel analysis, 50 
μg protein lysate (quantified using BioRad DC Protein Assay) was reacted with 1 mM tris(2-
carboxyethyl)phosphine (TCEP; Sigma), 20 μM TAMRA azide (Click Chemistry Tools), 1 mM 
CuSO4, and 100 μM Tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine (TBTA; Cayman) for 1 
hour at room temperature and the samples were heated at 70 °C for 5 minutes before being 
resolved by 12 % SDS-PAGE gels (180 V; 75 minutes) and imaged using Azure c600 (Azure 
Biosystems). They were then analyzed by western blot. 
Western blot analysis 
Gels were transferred to a methanol-activated Immobilon-FL membrane (Millipore) for western 
blot analysis. The transfer step was at 75 V for 2 hours at 4 °C in 25 mM Tris-base, 192 mM 
glycine, 10 % methanol buffer. Membrane was blocked in Odyssey Blocking Buffer (LI-COR) 
and incubated for 16 hours at 4 °C in primary antibody solutions prepared in Odyssey Blocking 
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Buffer supplemented with 0.2 % (v/v) Tween-20. Membrane was washed using Tris-buffered 
saline and 0.5 % (v/v) Tween-20 (TBS-T) before incubation with species-matched secondary 
antibody solutions for 1 hour at room temperature. For the DHHC and ABHD17 co-expression 
and metabolic labeling studies, the secondary antibody solutions contained either an anti-rabbit 
AlexaFluor 647 (to label GFP-tagged ABHD17) or anti-mouse horseradish peroxidase (HRP)  
(to label HA-tagged DHHC). HRP blots were developed using West Pico PLUS 
Chemiluminescent Substrate (Thermo) and the chemiluminescence signal detected by Azure 
c600 (Azure Biosystems) while blots treated with the AlexaFluor 647 secondary were imaged 
directly using the Cy5 and Cy3 channels for AlexaFluor 647 and TAMRA-azide signal. Images 
were processed using ImageJ software (NIH) and protein band measurements were calculated in 
Image Studio Lite (LI-COR). Bar graphs were plotted using RStudio. 
For the remaining experiments, the secondary antibody was the species-matched HRP antibody 
and the blots were processed as described above.  
Table 2-1 Antibody information 
Target Protein (Dilution) Product Information 
HA (1:1000) Roche 11583816001 
6xHis (1:1000) ThermoFisher MA121315 
FLAG-M2 (1:5000) Sigma F1804 
ABHD17A (1:500) Aviva Systems Biology ARP67573_P050 
ABHD17B (1:500) Abcam ab187665 
Pan-RAS (1:1000) Millipore 50-171-675 
GFP (1:1000) Cell Signaling Technology 2956S 
Tubulin (1:2500) Sigma T6074 
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Anti-rabbit AlexaFluor 647 
(1:1000) 
ThermoFisher A32733 
Anti-mouse HRP (1:1000) Invitrogen PI3243 
Anti-rabbit HRP (1:1000) ThermoFisher 32460 
 
Cloning, expression and purification of ABHD17 fusion proteins in E.coli and HEK-293T 
Plasmids expressing different fusion-tagged ABHD17 were created via restriction digest and 
ligation into p6xHis, pMBP and pGB1 (Protein Core in the Center for Structural Biology 
(Life Science Institute, University of Michigan). The mouse ABHD17 gene was amplified from 
plasmids previously made in the lab 76 and ligated using SspI and BamHI sites. BL21 (DE3) 
E.coli cultures were grown at 37 ˚C to OD600= 0.8 and the temperature was reduced to 18 ˚C for 
1 hour before induction with 0.4 mM IPTG for 16 hours at 18 ˚C. Cell pellets were resuspended 
in 50 mM HEPES, 300 mM NaCl, 10% Glycerol, 2 mM 2-Mercaptoethanol and 0.005% 
IGEPAL buffer, lysed using a microfluidizer and centrifuged at 16000 rpm for 30 minutes. The 
cleared supernatant was incubated with Talon cobalt affinity beads (Clontech) for 1 hour, washed 
with 50 mM HEPES, 150 mM NaCl and 1 mM imidazole buffer. The protein was eluted using 
50 mM HEPES, 150 mM NaCl and 150 mM imidazole buffer and dialyzed overnight to remove 
excess imidazole, yielding ~ 2.0 mg/mL. Sample aliquots were supplemented with 10 % glycerol 
and stored at −80 °C. To verify the activity of the enzymes, the purified protein samples were 
also incubated with 1 μM FP-TAMRA (generous gift from Gordon Amidon (University of 
Michigan, College of Pharmacy) for 30 minutes at room temperature prior to boiling with SDS-
loading buffer (50 mM Tris-Cl, pH 6.8, 2 % (w/v) SDS (sodium dodecyl sulfate; electrophoresis 
grade), 0.1 % (w/v) bromophenol blue, 10 % (v/v) glycerol and 100 mM 2-mercaptoethanol). 
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Samples were resolved by 12 % SDS-PAGE gels (180 V; 75 minutes) and imaged using Azure 
c600 (Azure Biosystems). 
ABHD17 protein was also expressed in HEK-293T using pcDNA3 plasmids with a FLAG-6xHis 
C-terminal tag. 76 Cells were cultured as previously described and at 90 % confluency, they were 
transfected using polyethylenimine (PEI; Alfa Aesar). Cells were collected the next day and 
washed in cold DPBS (Invitrogen) before storage at  −80 °C. Cells were resuspended in 25 mM 
HEPES pH 7.5, 25 mM NaCl, 1 % (w/v) n-dodecyl-β-Dmaltopyranoside (DDM, Anatrace) 
buffer for 1 hour at 4 °C. After removal of insoluble material by ultracentrifugation (100,000 × g, 
45 minutes, 4 °C), the supernatant was incubated with Talon cobalt resin (Clontech) for 1 hour at 
4 °C. Resin was washed using 25 mM HEPES pH 7.5, 25 mM NaCl, 1 mM imidazole buffer and 
protein was eluted with 25 mM HEPES pH 7.5, 25 mM NaCl, 150 mM imidazole. Protein was 
buffer exchanged in 25 mM HEPES pH 7.5, 25 mM NaCl to remove excess imidazole and 
concentrated using Amicon Ultra centrifugal filters (Millipore). Protein aliquots were 
supplemented with 10 % glycerol before storage at −80 °C. Alternatively, protein was also 
purified using anti-FLAG M2 magnetic beads (Sigma) to reduce non-specific proteins that co-
elute during Co resin affinity purification. The wash buffer contained 25 mM HEPES pH 7.5, 25 
mM NaCl and the elution buffer was 25 mM HEPES pH 7.5, 25 mM NaCl and 0.1 mg/mL 
FLAG peptide (Sigma).  
FP-TAMRA labeling time course to compare ABHD17A expressed from E.Coli and HEK-
293T 
Corresponding bands from FP TAMRA and 6xHis blot were quantified using Image Lite Studio 
(LI-COR) so that fluorescence signal (FP-TAMRA) was normalized with respect to protein 
 49 
abundance (6xHis band). Plotted values were calculated by dividing all normalized values with 
the maximum signal at 60 minutes. Plot was generated using Graphpad Prism 6.  
In vitro assays to test depalmitoylase activity on lipidated NRAS (17-ODYA click chemistry 
and 5-TMRIA labeling assay) 
Enzyme was diluted to 200 nM using 0.1 M phosphate pH 7.4, 50 mM NaCl, 0.03 % DDM and 
either 0.5 % NP-40 or 0.5 % TritonX buffer. 1.25 μM NRAS (labeled with 17-ODYA) was 
added to the enzyme in a total volume of 25 µL and incubated for 45 minutes at 37 ˚C. Then, 25 
µL of click reaction mixture was added (1 mM TCEP, 20 μM TAMRA azide, 1 mM CuSO4, and 
100 μM TBTA) for 45 minutes at room temperature. For the no enzyme sample, NRAS was 
instead mixed with 25 µL 0.1M HA or 25 µL buffer. Finally SDS loading buffer was added to 
the samples and they were heated at 75 ˚C for 5 minutes before being resolved by SDS-PAGE, 
imaged using the Azure c600 and further analyzed by western blot.  
For the iodoacetamide-TAMRA experiment, a similar protocol to the one outlined in the APEGS 
section was used. But instead of adding 5k-mPEG probe after hydroxylamine treatment, 
iodoacetamide-TAMRA was added to label any new cysteines that would be depalmitoylated by 
ABHD17.   
Resorufin acetate assay for inhibitor screening 
Steady-state kinetic assays were performed as previously described. 119 The rate of hydrolysis of 
resorufin acetate was determined for different compounds using the wild-type and the catalytic-
dead enzyme (GB1-ABHD17A-S190A and GB1-ABHD17B-S170A) to subtract any 
spontaneous hydrolysis. Resorufin acetate (Sigma) in DMSO was titrated at various 
concentrations as 2 μL aliquots in clear-bottom 96-well plates (Greiner bio-one), as well as 2 μL 
aliquots of 20 μM inhibitor in DMSO. Enzymes were diluted to 200 nM with PBS pH 6.5 
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supplemented with 0.1 g /L pluronic F127 (Sigma) and 96 μL was quickly dispensed to each 
well and mixed by pipetting up and down multiple times, with each enzyme being tested in 2 
separate runs and 4 replicates per substrate concentration. Fluorescence was measured on a 
Tecan F500 plate reader (525/35 nm excitation filter, 600/10 nm emission filter, and a 560 LP 
dichroic filter) for every 35 seconds for a total of 15 minutes. The slope of the background-
subtracted (catalytic dead) fluorescence in the beginning 5 minutes was used to generate initial 
reaction velocities, which were then processed in Graphpad Prism 6 to derive Km and Vmax 
values. Ki values were also calculated using a similar approach, by pre-incubating 200 nM 
enzyme with a range of inhibitor concentrations for 30 minutes at room temperature before 
adding 50 μM substrate and running the experiments in triplicates per inhibitor concentrations. 
Data was then processed in Graphpad Prism 6. 
Table 2-2 Structure of compounds used during inhibitor screening 











































































S-acylation describes a reversible post-translational modification, regulated by DHHC 
palmitoyltransferases which predominantly transfer a 16-carbon fatty acyl group to cysteines via 
a thioester link. The reverse reaction is catalyzed by depalmitoylases, including APT1, APT2 and 
ABHD17. This cycle facilitates the trafficking and function of proteins involved in various 
physiological processes, including the oncogenic RAS GTPase, where membrane tethering 
influences its ability to transform cells. Despite the development of chemical tools to better study 
S-palmitoylated proteins, it remains challenging to identify the sites that are modified. Here, we 
applied an acyl-RAC proteomics workflow to identify sites of acylation in mouse embryonic 
fibroblasts, which are engineered to express single RAS isoforms. Our results demonstrate that 
our method is comparable to other reported datasets, and we observed palmitoylated sites that 
were not previously annotated. Our method was also applied to identify substrates of ABHD17A; 
however, our results indicate that ABHD17A may not function as a depalmitoylase. The 
workflow described here can be further improved by additional informatics, and can be a 
valuable, more high-throughput strategy to identify substrates of DHHC enzymes, which are 
expressed as 23 distinct proteins.     
 
‡ This chapter includes contribution from Melanie S. Cheung See Kit, who performed all the experiments. 
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3B. Background 
Protein S-acylation is commonly known as S-palmitoylation since C16:0 palmitate is the 
predominant fatty acid chain that gets attached to cysteines via a thioester bond. A 2011 
computational survey of putative post-translational modifications (PTMs) from Swiss-Prot 
identified S-Palmitoylation as the 5th most frequent PTM.132 This labile PTM is catalyzed by the 
DHHC family of palmitoyl transferases, which has a Cys-rich domain containing a conserved 
Asp-His-His-Cys (DHHC) motif. Protein depalmitoylases, including acyl-protein thioesterases 1 
and 2 (APT1 and APT2) and the α/ β hydrolase domain-containing protein 17 (ABHD17), 
catalyze the reverse process, during which the palmitoyl group gets hydrolyzed. Protein 
palmitoylation has been shown to regulate the cellular trafficking of proteins across various 
physiological processes. For example, the oncogenic HRASG12V mutant requires membrane 
tethering to cause cellular transformation and this is abrogated by a palmitoyl-deficient 
HRASG12V mutant.27 Postsynaptic density (PSD)-95 is a scaffolding protein involved in synaptic 
development and function; palmitoylation at Cys3 and Cys5 are required for its postsynaptic 
targeting133 and it has been shown to be depalmitoylated by ABHD17.56  
ABHD17 is expressed as three main isoforms (A, B, and C) and contains a cysteine-rich 
N-terminal domain important for S-palmitoylation and membrane localization.76 Overexpressed 
ABHD17A is reported to depalmitoylate and mislocalize NRAS.61 In addition, a recent genome-
wide CRISPR screen in AML cell lines identified ABHD17B as an essential gene in NRAS 
dependent THP-1 cells and NRas-dependent Ba/F3 cells.111 So far, cell-based studies have 
focused on specific ABHD17 substrate targets; yet no proteome-wide approach has been used to 
identify other substrates depalmitoylated by ABHD17. 
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The study of S-palmitoylation using bottom-up proteomics methods, has remained 
challenging owing to the hydrophobic and labile nature of the thioester-linked S-palmitoylated 
peptides. There has been active development of biochemical assays that either metabolically 
incorporate alkyne fatty acids analogs to sites of palmitoylation (which can then be captured by 
bioorthogonal enrichment76) or use hydroxylamine to selectively replace palmitoylation with 
affinity enrichment probes.120, 88 The alkyne fatty acid derivative, 17-octadecynoic acid (17-
ODYA), is added to cells where it can be processed to form its coenzyme (coA) conjugate, 
which is transferred to endogenous sites of S-palmitoylation by DHHC enzymes. This method is 
useful for dynamic studies of palmitoylation turnover since cells can be collected at different 
time points and the cell lysates can be tagged by copper-catalyzed azide alkyne addition 
(CuAAC) to azides linked to fluorophores or biotin for gel-based or mass spectrometry analyses 
respectively. This approach has been widely used to characterize S-palmitoylated proteins across 
multiple cell lines9, 89 and organisms.95 However, the alkyne fatty acid can be metabolized to 
other phospholipids and incorporated into other protein modifications, and high levels of 
palmitate can trigger oxidative stress,99 causing free thiols to be trapped in disulfide bonds or 
glutathione adducts. Additionally, proteins with slow palmitoylation turnover may not have a 
free Cys available to incorporate the alkyne fatty acid analog. 
An alternative approach is based on hydroxylamine-switch strategies, where 
hydroxylamine selectively cleaves all thioesters across the proteome to release free thiols that 
can then be captured. Unlike metabolic labeling, this technique can be used to profile steady-
state palmitoylation levels in primary tissues. The biochemical assay starts with addition of 
tris(2-carboxyethyl)phosphine (TCEP) to reduce disulfides and an alkylating agent such as N-
ethylmaleimide (NEM) or iodoacetamide (IAM) to block free thiols. Then, neutral 
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hydroxylamine can be added to hydrolyze thioester bonds, and the resulting thiols are captured 
using a pyridyl disulfide resin (acyl-resin assisted capture; acyl-RAC)88 or a pyridyl disulfide 
biotin conjugate for subsequent streptavidin resin enrichment (acyl biotin exchange; ABE).120 It 
is important to note that this method is not specific to S-palmitoylation, and other endogenous 
thioester-linked proteins such as ubiquitin ligases and lipoamide-dependent hydrolases are also 
detected. While still bound to the resin, proteins can be enzymatically digested to generate 
peptides for mass spectrometry (MS) analysis.  
The enzymatic (usually tryptic) peptides present in the supernatant are the ones often 
annotated by MS to generate datasets of palmitoylated proteins.87, 116 In a few cases, additional 
steps are performed to allow for identification of the peptides containing the S-palmitoylation 
site(s). The tryptic peptides in the supernatant are removed and the resin is washed and treated 
with TCEP again to release the peptides. These are either directly analyzed or blocked using a 
second alkylating reagent. A study of mouse forebrain tissue by site-specific acyl biotin 
exchange (ssABE) revealed 906 putative sites of palmitoylation mapped to 641 proteins134 while 
acyl-RAC site analysis, comparing normal mice liver tissue and tissue deficient in DHHC13, 
identified 400 palmitoylation sites for 254 candidate substrates of DHHC13.135 Finally, in the 
instance where a second alkylating reagent was used to block the free cysteine, 347 proteins were 
identified from naïve and LPS/IFN-γ stimulated RAW264.7 macrophages.136 These approaches 
provide a long list of putative sites that can be compared against the S-palmitoylation database 
SwissPalm,31 thereby allowing the identification of proteins that have been previously annotated 
across multiple experimental methods. Additionally, sites of palmitoylation can be validated 
using other biochemical means, such as introducing Cys to Ala mutants of the putative site. 
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 Here, we applied current acyl-RAC proteomics workflow (Figure 3-1) to identify 
putative sites of palmitoylation in mouse embryonic fibroblast (MEF) cell lines engineered to 
express individual RAS isoforms.137 For our workflow, we used iodoacetamide (IAM) as the first 
alkylating reagent instead of methyl methanethiosulfonate (MMTS) to prevent competition with 
the thiopropyl beads in case of incomplete removal of excess alkylator. After eluting the tryptic 
peptides off the beads, we added a second alkylating reagent, MMTS to make Cys adducts that 
we could specifically search for during data analysis. For MEF cells expressing NRASWT and 
HRASWT, we identified 2989 sites belonging to 1533 proteins and 3695 sites mapped to 1796 
proteins respectively. Further validation is required to compare our results to predicted sites of S-
palmitoylation available from CSS-Palm,138 as well as biochemically confirm the sites of 
palmitoylation in proteins of interest. Additionally, we applied a similar strategy in an effort to 
find putative substrates of ABHD17A. However, comparison of samples, overexpressing 
ABHD17A as the wild-type or catalytically inactive (Ser to Ala mutant; SA), did not result in 
any significant changes in levels of palmitoylated peptides. In agreement with our proteomics 
data, analysis of NRAS palmitoylation by gel-based acyl-RAC did not show any significant 
changes between overexpression of ABHD17A WT or ABHD17A SA. Further testing of our 
method, using other enzymes involved in S-palmitoylation such as DHHCs or APT1/2, can 




Figure 3-1 Analysis of S-palmitoylation by acyl-RAC workflow. 
Samples can either be analyzed by proteomics to provide sites of palmitoylation across a proteome or by SDS-PAGE gel and 
western blot for individual proteins. TCEP = tris(2-carboxyethyl)phosphine; IAM = iodoacetamide; NH2OH = hydroxylamine; 
DTT = dithiothreitol; MMTS = methyl methanethiosulfonate; LC-MS/MS = liquid chromatography-tandem mass spectrometry; 
SDS-PAGE = sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
 
3C. Results and discussion 
3CI. Identification of putative sites of S-palmitoylation in mouse embryonic fibroblasts (MEF) 
cells by site-specific acyl-RAC proteomics  
We decided to modify available acyl-RAC methods by using iodoacetamide (IAM) as the 
first alkylating reagent instead of methyl methanethiosulfonate (MMTS) and use MMTS in the 
later alkylating step to block thiols on peptides eluted off the thiopropyl beads. This facilitated 
our data analysis as we searched for Cys modified with MMTS (45.988 Da) as our sites of S-
acylation. We used MEF cells expressing either HRAS or NRAS isoforms to test our acyl-RAC 
workflow (Figure 3-1) and identify sites of S-acylation from triplicate samples with or without 
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hydroxylamine (HA; NH2OH) treatment. Peptides were analyzed using a nanoLC-MS/MS 
Orbitrap, then identified and quantified using the MaxLFQ algorithm in MaxQuant,139 designed 
for label free quantification. A statistical analysis (t test, permutation-based, FDR = 0.01 and s0 
= 1) was applied in order to identify peptides that were at least significantly enriched two-fold 
(Figure 3-2). For MEF cells expressing NRASWT and HRASWT, we identified 2989 sites 
belonging to 1533 proteins and 3695 sites mapped to 1796 proteins respectively. We used the 
SwissPalm database to compare our results to previously published datasets of S-palmitoylated 
proteins from mouse cells or tissue samples, showing that about half or more of our identified 
proteins have not yet been annotated as being S-acylated. Comparative studies between 
bioorthogonal metabolic labeling and hydroxylamine-switch methods116, 136 have shown that they 
can detect distinct subsets of proteins, which could explain why some of the proteins from 
SwissPalm were not identified in our results.    
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Figure 3-2 S-acylated peptides in RAS mouse embryonic fibroblasts. 
Volcano plots show S-acylated peptides (labeled with MMTS) that were significantly enriched from (A) NRAS MEF and (B) 
HRAS MEF cells (p < 0.01, Log2 (Fold change) ≥ 1) in a site-specific acyl-RAC proteomics experiment (n = 3, label free 
quantification). Venn diagrams display the overlap between the proteins identified in our experiments and the SwissPalm 
database containing published proteomic datasets of S-palmitoylation proteins.31 
 
Our goal was to identify sites of S-palmitoylation and Table 3-1 contains proteins from 
our dataset, that are known to be palmitoylated based on their UniProt Knowledgebase post-
translational modification entry. We also compared our results to the SwissPalm database and 
showed similar site identifications to other published datasets which used different methods of 
enrichment, including acyl-RAC,135 acyl biotin exchange,134 and phenyl mercury enrichment.140 
Additional work is still needed to conduct such an analysis on a larger scale and leverage the 
wealth of information presented by large proteomic datasets. Computational tools can be 
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developed to help determine how our experimental sites of S-acylation measure up to predicted 
sites from CSS-Palm.  
Table 3-1 Subset of identified sites of S-palmitoylation compared to SwissPalm database.  










protein 2 (SCRB2) 8 274 Shen et al 
 HC: 4, 5 
Glutamine synthetase 
(GLNA) 
5 99 Shen et al  
 6 346 Gould et al, Shen et al 
 
4 229 n/a  
Calnexin (CALX) 
21 367 n/a  
HC: 504; MC: 8 8 195 Gould et al  
CD81 antigen 
(CD81) 
30 190 n/a  
HC: 6, 9, 227; 
MC: 156,  228 20 156 Shen et al 
 
157 Shen et al  
CD9 antigen  (CD9) 20 
150 Collins et al  HC: 9, 76, 77, 
150, 151, 216, 
217; MC: 85 151 Collins et al 
 
165 Collins et al  
Ras-related protein 
R-Ras2  (RRAS2) 27 183 n/a 
 HC: 199, 201 
Alpha/beta hydrolase 
domain-containing 
protein 17B (AB17B) 
11 120 Collins et al  HC: 10, 11, 14, 15, 18, 39 
Palmitoyltransferase 
ZDHHC6 (ZDHC6) 6 
328 Collins et al Abrami et al 
HC: 5, 20, 135, 
136, 328; MC: 
101, 329, 392, 
396 329 Collins et al Abrami et al 
n/a = not annotated; HC = high confidence; MC = medium confidence. Shen et al135; Gould et al140; Collins et al134; Abrami et 
al.52 
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3CII. Profiling putative substrates of ABHD17 depalmitoylases by site-specific acyl-RAC 
proteomics analysis  
After showing that we could obtain S-palmitoylation site analysis comparable to other 
published datasets, we decided to use our workflow to identify substrates of ABHD17A 
depalmitoylase. We initially tried a CRISPR interference (CRISPRi) strategy targeting 
ABHD17A and 17B expression at the transcriptional level141 to generate cell lines with repressed 
expression of the enzymes. While we could obtain ABHD17B knockdown in HAP1 cells 
(Figure 3-3), our ABHD17A knockdown in THP-1 cells was not stable, and the cells recovered 
protein expression after multiple cell passages despite antibiotic selection (Figure 3-4). In the 
future, an alternative method such as an inducible shRNA system can be used to address cells 
recovering expression of essential genes.  
 
Figure 3-3 A CRISPRi strategy was employed to target expression of ABHD17B in HAP1 cells. 




Figure 3-4 Acyl-RAC gels verifying expression and S-palmitoylation of ABHD17A in THP-1 cells following CRISPRi knockdown. 
ABHD17A was initially knocked down in THP-1 cells; however after passaging the cells, ABHD17A expression was recovered.  
 
We altered our approach and instead overexpressed ABHD17 either as the wildtype 
active enzyme or catalytically inactive S190A mutant. Using the same workflow described 
earlier, we found that there were no significant changes in palmitoylation levels when 
ABHD17A (WT or S190A) is overexpressed in NRAS MEF cells (Figure 3-5).  
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Figure 3-5 No significant changes in S-acylation levels observed during overexpression of ABHD17A WT and S190A (mutant) in 
NRAS MEF cells.  
Volcano plot shows S-acylated peptides (labeled with MMTS) that were significantly enriched from NRAS MEF overexpressing 
either the active ABHD17A WT or catalytic inactive S190A mutant (p < 0.01, Log2 (Fold change) ≥ 1) in a site-specific acyl-
RAC proteomics experiment (n = 3, label free quantification). Venn diagram displays the overlap between the proteins identified 
in the experiments and the SwissPalm database. 
 
To validate our proteomics result, we performed gel-based acyl-RAC and analyzed 
NRAS palmitoylation by western blot (Figure 3-6). Again we did not see any significant 
changes in endogenous NRAS S-acylation upon overexpression of ABHD17 as the active 
enzyme (WT), catalytically inactive mutant (S190A) and the palmitoylation-deficient Δ19N 
truncation. This suggests that in our biological system, NRAS is not depalmitoylated by 
ABHD17A, nor does it depalmitoylate other protein substrates. As secondary validation, 
reciprocal strategies should be devised to either knockdown ABHD17A expression using a 
different gene editing system or develop selective and potent inhibitors of the enzyme. 
Moreover, there are no in vitro studies that demonstrate the depalmitoylase activity of ABHD17, 




Figure 3-6 NRAS palmitoylation level measured by acyl-RAC. 
ABHD17A was overexpressed as the wildtype, S190A (catalytically inactive) and Δ19N (truncation of the first 19 amino acids) 
in NRAS MEF cells and levels of NRAS palmitoylation measured by acyl-RAC, combined with western blot analysis. 
 
3D. Conclusion 
After applying our acyl-RAC proteomics methods, we identified sites of S-palmitoylation 
from MEF cells expressing either NRASWT or HRASWT. The proteins, along with their putative 
sites of palmitoylation, were compared to the SwissPalm database, which curates published 
proteomics datasets of S-palmitoylated proteins. Though our results demonstrate that a small list 
of putative sites are similar to ones previously identified using different methods of enrichment, 
we still need to improve our workflow and implement computational programming methods to 
analyze the whole dataset efficiently. Finally, we applied our workflow in attempt to identify 
putative substrates of ABHD17 enzymes. However, both our proteomics and gel-based results 
suggest that overexpressed ABHD17A does not cause significant changes in the palmitoylation 
levels in our NRAS MEF cell line, hinting that ABHD17 may influence palmitate turnover 
through a different mechanism. Nonetheless, this workflow could be applied for relatively high-
throughput identification of putative substrates of DHHC palmitoyl transferases across various 
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biological systems. given that there are 23 DHHC enzymes expressed in humans. Additionally, it 
can be used to identify novel depalmitoylases by characterizing less studied members of the 
serine hydrolase superfamily. 
3E. Experimental 
Cell culture and transfection 
“RASless” mouse embryonic fibroblast (MEF) cells were obtained from the National Cancer 
Institute RAS Initiative. They were cultured in Dulbecco’s Modified Eagle Media (DMEM; 
Invitrogen) supplemented with 1 % (v / v) 10000 Units / mL penicillin-streptomycin 
(Invitrogen), 4.5 g / L D-Glucose, 2 mM L-Glutamine, 110 mg / L sodium pyruvate, and 10 % (v 
/ v) fetal bovine serum (GE Healthcare Life Sciences) and at 90 % confluency, they were 
transfected using polyethylenimine (PEI; Alfa Aesar) and Opti-MEM (reduced serum media; 
ThermoFisher). Cells were collected the next day and washed in cold DPBS (Invitrogen) before 
storage at  −80 °C for future use. 
Acyl-resin assisted capture (acyl-RAC)  
Cell pellets were first lysed in 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA buffer 
(buffer 1) by sonication and diluted using 50 mM HEPES pH 7.4, 6 M Urea, 1 mM EDTA, 1% 
SDS buffer (buffer 2). Proteins were then reduced using 20 mM tris(2-carboxyethyl)phosphine 
(TCEP; Sigma), pH 7 for 30 minutes at room temperature, followed by alkylation with 50 mM 
iodoacetamide (IAM; Sigma) for one hour in the dark. Proteins were then precipitated by 
chloroform-methanol extraction to remove excess reagents before resuspendion in buffer 2, 
without 6 M urea (which is not compatible with protein quantification assay). Protein 
concentration was measured using DC protein assay (Biorad). An aliquot was saved for gel-
based analysis where the sample was first incubated with 0.5 M hydroxylamine (HA, Sigma), pH 
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7 for 15 minutes before adding 1 μM Tetramethylrhodamine-5-Iodoacetamide Dihydroiodide (5-
TMRIA (noted IAM-TAMRA); Thermo) for 30 minutes.  
The remaining sample was split equally into 2 tubes for the enrichment analysis.  For plus HA 
treatment, 0.5 M HA, pH 7 was added to the sample in addition to ~ 20 mg slurry of pre-
activated thiopropyl sepharose 6B beads (Sigma). For the minus HA sample, buffer 2 was used 
instead to match the volume of the plus HA sample. Samples were incubated for 2 hours at room 
temperature. The beads were then thoroughly washed five times with buffer 2, followed by 
another five times using 50 mM HEPES, pH 7.4 buffer (buffer 3). For the western blot analysis, 
beads were resuspended in 1X loading buffer (10% glycerol, 62.5 mM tris pH 6.8, 1% 2-
mercaptoethanol, 0.05% bromophenol blue, and 1% SDS) and heated for 5 minutes at 90 °C. The 
supernatant analyzed by SDS-PAGE. For the proteomic analysis, beads were resuspended in 
buffer 3 and incubated with Trypsin/ LysC mix (Promega) at 37 °C overnight. The next day, the 
supernatant containing the digested peptides was collected. The beads were washed five times 
with buffer, followed by treatment with 25 mM dithiothreitol for 45 minutes at 70 ºC. Eluted 
peptides were transferred to a new tube and the beads were washed three times with buffer 3. 
After pooling the eluted peptides with the three washes, the peptides were alkylated using 60 
mM methyl methanethiosulfonate (MMTS; Sigma) for 2 hours at 37 ºC. Samples were then 
desalted with an Oasis PRIME HLB μElution Plate (Waters) and dried in a Thermo Savant 
SpeedVac before storage at -80 °C. Peptides were resuspended in 0.1 % TFA in LC-MS grade 
H2O for LC-MS/MS analysis. 
Western blot 
Gels were transferred to a methanol-activated Immobilon-FL membrane (Millipore) for western 
blot analysis. The transfer step was at 75 V for 2 hours at 4 °C in 25 mM Tris-base, 192 mM 
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glycine, 10 % methanol buffer. Membrane was blocked in Odyssey Blocking Buffer (LI-COR) 
and incubated for 16 hours at 4 °C in primary antibody solutions prepared in Odyssey Blocking 
Buffer supplemented with 0.2 % (v/v) Tween-20. Membrane was washed using Tris-buffered 
saline and 0.5 % (v/v) Tween-20 (TBS-T) before incubation with species-matched secondary 
antibody solutions for 1 hour at room temperature. 
Table 3-2 Western blot antibody information 
Target Protein (Dilution) Product Information 
6xHis (1:1000) ThermoFisher MA121315 
FLAG-M2 (1:5000) Sigma F1804 
ABHD17A (1:500) Aviva Systems Biology ARP67573_P050 
ABHD17B (1:500) Abcam ab187665 
Pan-RAS (1:1000) Millipore 50-171-675 
Anti-mouse HRP (1:1000) Invitrogen PI3243 
Anti-rabbit HRP (1:1000) ThermoFisher 32460 
 
LC-MS/MS analysis 
Label-free biological triplicates (n =3) were prepared per condition and analyzed by LC-MS/MS 
using an UltiMate 3000 RSLCnano liquid chromatography system (Dionex) coupled to an 
Orbitrap Fusion Lumos Tribrid mass spectrometer (ThermoFisher Scientific) equipped with an 
EasySpray source (ThermoFisher Scientific). Each sample was resolved using a nano-capillary 
reverse phase column (Acclaim PepMap 100 C18, 2 μm, 75 μm i.d. x 50 cm, Thermo Scientific), 
300 nL / min flowrate and 120 minutes gradient (2-30 % acetonitrile/ 0.1 % formic acid). The 
mass spectrometer was programmed to collect one MS1 scan (Orbitrap; 60,000 resolution; AGC 
 68 
target 2x105; max IT 50 ms) followed by data-dependent, “Top Speed” (3 seconds) MS2 scans 
(collision induced dissociation; Orbitrap; 30,000 resolution; AGC 1x105; max IT 22 ms). 
MS data processing and analysis 
The data was processed using MaxQuant version 1.6.5.0 and searched against a UniProt mouse 
sequence database (55197 sequences; downloadeded May 2019). Cysteine 
carbamidomethylation and cysteine modified by MMTS (Palmitoylation sites) were used as 
variable modifications. For the identification, the false discovery rate was set to 0.01 for proteins, 
peptides and sites while the minimum peptide length was set to seven amino acids. Other 
MaxQuant parameters were kept as the default setting. Label free quantification was performed 
using the “match between runs”. Dataset was further analyzed using Microsoft Office Excel 
2016, BioTools.fr (for Venn diagrams) and Perseus version 1.6.5.0. Data was first filtered to 
remove reverse contaminants and to keep 3 valid values for plus HA samples. Replicates were 
grouped together and log2 of the label free intensities was calculated. Missing (NA) values 
resulting from zero values for the minus HA samples were imputed with random numbers from a 
normal distribution (imputation criteria: width 0.3 and down shift 1.8). A two-sample test 
(permutation-based, 250 permutations, FDR = 0.01 and S0 value = 1) was performed to compare 
the plus HA sample (S-acylated proteins) with minus HA (background) and find significant 
peptides that were enriched with a fold change of at least 2. The Venn diagrams were  
For the samples where ABHD17A WT and 17A SA were overexpressed, the data was filtered so 
that all 6 values for the two sets of triplicates were required and no missing value imputation was 
performed. A two-sample test (permutation-based, 250 permutations, FDR = 0.01 and S0 value = 
1) was performed to compare the ABHD17A WT sample (plus HA) with ABHD17A SA sample 
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(plus HA) and find significant peptides that were enriched with a fold change of at least 2.   
CRISPRi of HAP1 and THP-1 cells  
HAP1 cells were a generous gift from Gisou van der Goot (EPFL), and were cultured in Iscove′s 
Modified Dulbecco′s Medium (IMDM / Invitrogen) supplemented with 1 % (v / v) 10000 Units / 
mL penicillin-streptomycin, and 10 % (v / v) fetal bovine serum. THP-1 cells were cultured in 
Roswell Park Memorial Institute medium (RPMI 1640 / Invitrogen) supplemented with 1 % (v / 
v) 10000 Units / mL penicillin-streptomycin, and 10 % (v / v) fetal bovine serum. Using 
plasmids ordered from Addgene, optimized sgRNAs for ABHD17142 (Sigma) were cloned into 
CRISPRi plasmids  as previously described.143 Cells were transduced with virus and allowed to 
grow before dilution to single cells in 96-wells plate. Cells were expanded from individual wells 
and screened for ABHD17 expression by western blot.  
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Chapter 4 Conclusion and Future Directions 
 
4A. Conclusion 
S-palmitoylation is a dynamic post-translational modification that facilitates the 
trafficking and function of proteins. It is catalyzed by DHHC palmitoyltransferases, which 
usually attach a 16-carbon fatty acyl group to specific cysteines. Depalmitoylases can hydrolyze 
the thioester bond to participate in palmitate turnover and several enzymes have been reported to 
be depalmitoylases, including PPT1, APT1, APT2 and ABHD17 isoforms (A-C). This work 
focused on the biochemical characterization of the ABHD17 enzyme family in an effort to learn 
more about its cellular function and protein substrates.  
Chapter 2 demonstrated how similar the three ABHD17 isoforms are, whereby they are 
presumably processed through similar processing pathways following protein production. We 
purified recombinant enzyme from both E.coli and HEK-293T cells to investigate the impact of 
S-palmitoylation on enzyme activity, and demonstrated that the rates of activity are similar based 
on the reaction of active site serine residue with FP-TAMRA, is comparable. Our initial 
development of assays, to determine whether recombinant ABHD17 can depalmitoylate a protein 
substrate in vitro were inconclusive and require additional effort to obtain a more definitive 
answer as to whether ABHD17 is a dedicated depalmitoylase. Given the physiological 
importance of the substrates ABHD17 is reported to depalmitoylate in vivo, it would be valuable 
to develop selective and potent inhibitors to further examine the cellular role of ABHD17. 
Similar to our lab’s past efforts to develop inhibitors for APT1 and APT2 enzymes, we also 
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assessed compounds with different scaffolds that were initially identified in a high-throughput 
screen. We demonstrated that while some compounds (benzoxazinone derivatives) were 
effective at inhibiting recombinant full-length enzyme and HEK-293T lysate overexpressing 
ABHD17, the compounds did not change the overall S-palmitoylation levels when added directly 
to growing cells.  Thus, future effort can be dedicated to exploring other derivatives of the 
benzoxazinones that are also active in vivo. 
Chapter 3 discussed the biochemical and analytical methods available to study S-
palmitoylation. Using our modified workflow, we obtained results similar to previously-
published studies in addition to finding new putative palmitoylation sites on proteins not 
previously known to have them. Our method can be strengthened by developing bioinformatics 
tools to allow for large-scale comparisons of experimental results to the SwissPalm database, and 
facilitate the discovery of palmitoylation sites that can be later validated using biochemical 
routes. We also decided to apply our workflow to identify the putative substrates of ABHD17. In 
this process, we obtained unexpected results that contradicted a published report where cell-
based assays were used to show that overexpressed ABHD17A depalmitoylates NRAS. 
Nevertheless, we have demonstrated that this method allows for the identification of sites of S-
palmitoylation and can be a valuable tool to expedite the study of other enzymes involved in the 
S-acylation cycle, such as DHHC palmitoyltransferases. 
The work presented here contributes to the understanding of ABHD17. However, 
numerous questions remain unanswered and would benefit from future studies. For example, the 
lipid substrate preference of ABHD17 remains unknown and would inform on their mechanism 
of action. There is still much to learn about the opposite side of S-palmitoylation cycle and 
regulation by DHHC enzymes. We hope that our modified workflow can spur more large-scale 
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proteomics studies to tease apart the contribution of specific DHHCs in regulating S-
palmitoylation across various biological contexts. 
4B. Future directions  
Additional effort is still needed to understand the mechanism of action of ABHD17 
enzymes. There has been some recent development of palmitoylated probes, which can be used 
to assess the depalmitoylating activity of ABHD17 isoforms. The depalmitoylation probes 
(DPPs) have been used to measure in vitro kinetics for APT1 and APT2; they were also added to 
cells to monitor endogenous depalmitoylase activity,74 hence allowing for the detection of APT1 
activity in the mitochondria.49 Furthermore, this study by Amara et al,144 presented quenched 
fluorogenic substrates, containing a palmitoylated cysteine that released the quencher molecule 
upon thioester hydrolysis, thus generating a fluorescence signal (Figure 4-1). These were used to 
test the activity of recombinant human APT1 and APT2, as well as PPT1 expressed from 
T.gondii. They demonstrated that the substrate was mainly processed by depalmitoylases since 
treatment with the non-specific inhibitor Palmostatin B blocked product formation in contrast to 
the common esterase substrate, 4-nitrophenyl octanoate. The authors also conjugated short 
peptides to their quenched fluorogenic substrates, with 2 amino acids flanking the Cys residue on 
each side, thereby creating a positional scanning library to map the substrate specificity of 
depalmitoylase enzymes. They then demonstrated that a Scribble-derived peptide sequence was 
preferentially hydrolyzed by APT2 and not APT1 or PPT1, corroborating a published cell-based 
study showing that APT2 was the enzyme depalmitoylating Scribble.57 Therefore, the probes 
discussed above can be used to test the in vitro depalmitoylase activity for ABHD17 and 
determine how different the isoforms are. 
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Figure 4-1 Quenched fluorogenic probe designed to measure depalmitoylase activity 
The substrate contains a palmitoylated Cys that can be hydrolyzed to release the quencher molecule. License was obtained to re-
use the published figure144 in this document. Copyright to the licensed content publisher Elsevier. 
 
 Considering how the co-crystal structures of APT1 and APT2 with their respective 
isoform-selective inhibitors were instrumental in distinguishing key residues that confer inhibitor 
selectivity and provide structural insight into the differences between the two enzymes,119 it 
would be valuable to pursue a similar route for ABHD17. The non-specific lipase inhibitor, 
HDFP has been shown to stabilize the melting temperatures of APT1 and APT2 by more than 10 
°C119 and could be used to mimic the long chain fatty acid of palmitate and aid in the co-
crystalllization of ABHD17. Having a solved structure in hand opens the possibility of taking 
computational approaches to (1) profile different types of lipid substrates to determine how they 
are accommodated in the enzyme active site to engage in the catalytic reaction and (2) simulate 
the docking of additional classes of compounds in an effort to find inhibitors targeting ABHD17.  
Fatty acid amide hydrolase (FAAH) is involved in endocannabinoid signaling in the 
nervous system145 and it has two important residues (Phe432 an d Trp531), present at the 
interface between two cavities that form the enzyme active site, which are gating residues 
mediating active site access.146 Molecular dynamics simulations, comparing the activity of wild-
type and double mutant (Phe432 and Trp531) enzymes embedded in a palmitoyl-2-oleoyl-
phosphatidylethanolamine (POPE) lipid bilayer, showed how the preferred fatty acid substrate, 
anandamide, is efficiently oriented into the active site to promote hydrolysis. Mutagenesis and 
kinetics experiments further confirmed the computational model.147 Hence, this study could be 
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extended to other lipid-processing enzymes such as ABHD17 to clarify their substrate selectivity 
and function. Computational docking of libraries of small molecules targeting KRASG12D mutant 
yielded candidate compounds that were then synthesized and shown to selectively bind to 
KRASG12D and inhibit activity in primary patient samples and mouse xenograft models.148 With a 
crystal structure of ABHD17, a similar strategy could be used to test new classes of ligands 
which would improve probe development to selectively target ABHD17.     
In chapter 3, we used an acyl-RAC proteomics approach to identify sites of S-
palmitoylation, where the palmitate group bound to the Cys was exchanged for an alkylating 
reagent following hydroxylamine treatment. However, this still remains an indirect method to 
measure sites of S-acylation. With the development of better analytical methods to address the 
challenge of this post-translational modification (PTM) being labile and hydrophobic, we would 
be able to directly assign the PTM site. Changing the column resin or adapting the mobile phase 
composition can extend quantitative proteomics to more hydrophobic peptides, thus allowing the 
direct analysis of the modified peptide and specific acyl chain. Efforts related to sample 
preparation methods to optimize acyl-thioester stability, separation, ionization, and 
fragmentation have not been explored outside of single peptide measurements. Another 
alternative would be to take a top-down proteomics approach, which has been used to study 
mutant KRAS4b purified from tumor samples proteoforms. The study identified proteoforms 
with specific PTMs under different cellular context, demonstrating the crosstalk between 
different PTMs in regulating activity of KRAS.149 
Overall, the proposed experiments would contribute to a better understanding of the 
mechanism by which ABHD17 engages substrates and develop better chemical probes to study 
ABHD17 function. In addition, development of analytical strategies to directly study S-
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palmitoylation would advance our understanding of how regulation of this PTM modulate 
important biological processes.  
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Appendix  Enrichment of S-palmitoylated Proteins for Mass Spectrometry 
Analysis‡ 
Abstract 
As the 10-year anniversary of their first introduction approaches, alkynyl fatty acids have 
revolutionized the analysis of S-palmitoylation dynamics, acting as functional mimics 
incorporated into native modification sites in cultured cells. The alkyne functional group 
provides a robust handle for biorthogonal Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 
to reporter-linked azides, forming a stable conjugate for enrichment for mass spectrometry 
analysis or in-gel fluorescence. Importantly, metabolic labeling enables time-dependent analysis 
of S-palmitoylation dynamics, which can be used to profile incorporation and turnover rates 
across the proteome. Here we present a protocol for cell labeling, click chemistry conjugation, 




‡ This appendix chapter includes a book section from Protein Lipidation, Methods and Protocols (Springer 2019).131 
My contribution includes assistance in writing. 
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Introduction 
Protein S-palmitoylation describes the long chain fatty acylation modification of cysteine 
residues in proteins.2, 150 zDHHC family protein acyltransferases catalyze acyl group transfer 
from long chain fatty acyl-CoAs to specific cysteine residues in protein substrates, which can 
then undergo spontaneous hydrolysis or enzyme-catalyzed depalmitoylation by protein 
depalmitoylases.1 Hundreds of membrane-associated proteins require S-palmitoylation for proper 
localization, trafficking, and function. Despite the prevalence of S-palmitoylation, proteome-
wide enrichment and analysis was confounded for decades by a lack of specific affinity reagents. 
The classic method for studying S-palmitoylation required metabolic addition of 3[H]-labeled 
fatty acids analogs, immunoprecipitation of select targets, and lengthy exposure times. The 
introduction of hydroxylamine-switch methods (acyl-biotin exchange86, acyl-RAC88, etc.) 
provided the first approach to enrich and annotate S-acylation, demonstrating the widespread 
modification of hundreds of proteins in protozoa94, single cell eukaryotes120, and mammals.87, 134 
While this method is especially useful for analysis of primary tissues, hydroxylamine-switch 
methods only measure the steady-state levels of S-palmitoylation, and thus cannot provide any 
information on incorporation dynamics or turnover rates. 
Alternatively, metabolic labeling with alkynyl fatty acid analogs has greatly simplified 
analysis of S-palmitoylation dynamics.151 The commercially available alkynyl fatty acid analog 
17-octadecynoic acid (17-ODYA) is metabolically incorporated into endogenous S-
palmitoylation sites, enabling Cu(I)-catalyzed azide-alkyne cycloaddition (click chemistry) to 
fluorophore-linked azides for in-gel fluorescence or to biotin-azide for enrichment and mass 
spectrometry analysis.76 This approach enables simple analysis of probe incorporation rates, as 
well as pulse-chase analysis of S-palmitoylation turnover dynamics.29, 96 When coupled to 
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quantitative mass spectrometry methods, 17-ODYA labeling and enrichment has identified S-
palmitoylated proteins with accelerated turnover kinetics, including proteins involved in cell 
polarity and growth.29, 57 Through these methods, it is now experimentally feasible to broadly 
profile S-palmitoylation dynamics in cultured yeast152, protozoa94, 95, and mammalian cells.2, 76, 
151 Here we present a workflow for multiplexed analysis of S-palmitoylation leveraging isobaric 
TMT quantitation by mass spectrometry. This protocol assumes collaboration with a mass 
spectrometry facility, able to perform the experiment and assist in any data analysis. 
 
Materials 
Use ultrapure water (prepared by purifying deionized water, to attain a sensitivity of 18 MΩ-cm 
at 25 °C) and analytical grade reagents. Use phosphate buffers throughout the protocol. Do not 
use Tris buffers or EDTA prior to performing the click reaction, since these reagents inhibit the 
copper(I)-catalyzed click chemistry reaction. Discard waste materials following the appropriate 
waste disposal regulations. 
 
Equipment and Supplies 
1. Cell culture facility including CO2 incubator and biosafety cabinets cell culture hoods.  
2. Branson Ultrasonics Sonifier S-450A Analog Ultrasonic Cell Disruptor/Homogenizer 
with double stepped tip (64 to 247 μm amplitude). 
3. Beckman Optima L-70 ultracentrifuge with Sorvall F50L-24X1.5mL microrotor. 
4. Absorbance spectrophotometer or plate reader to measure 700 nm absorbance 
measurements for protein quantitation. 
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5. 15 mL conical centrifuge tubes, 2 mL microcentrifuge tubes, 1.5 mL thick-walled 
microcentrifuge tubes (Beckman), 1.5 mL screw cap microcentrifuge tubes, mass 
spectrometry autosampler vials.  
6. SDS-PAGE gels and electrophoresis equipment, such as BioRad Mini-PROTEAN tetra 
cell vertical electrophoresis system with precast 10% SDS-PAGE gels, 4X SDS loading 
buffer supplemented with β-mercaptoethanol, SDS-PAGE running buffer, and pre-stained 
protein molecular weight ladder. 
7. Eppendorf 5810R tabletop centrifuge or equivalent with swinging bucket rotor for 15 mL 
tubes. 
8. Promega Vac-Man Vacuum Manifold. 
9. Poly-Prep chromatography column, 10 mL volume (Bio-Rad). 
10. Oasis HLB µElution plate (2 mg sorbent per well, 30 µm particle size; Waters) and 
vacuum manifold. 
11. Amersham Typhoon 5 Biomolecular Imager for in-gel fluorescence analysis. 
12. Thermo Savant SPD1010 SpeedVac Concentrator System. 
 
Chemicals and Reagents 
1. 20 mM 17-ODYA (1000x stock): 5.61 mg/ mL in DMSO (Cayman Chemical). Store 
aliquots at -80 °C. 
2. ODYA labeling medium: culture medium, dialyzed serum, any required supplements, 
and 20 µM 17-ODYA (1x). Sonicate the medium if necessary to dissolve 17-ODYA. 
3. 20 mM palmitic acid (1000x stock): 5.13 mg / mL in DMSO. Sonicate the medium if 
necessary to dissolve the palmitic acid. 
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4. Palmitic acid labeling medium: culture medium, dialyzed serum, any required 
supplements, and 20 µM palmitic acid (1x).  
5. Lysis Buffer: Dulbecco’s phosphate buffered saline (DPBS), 20 µM 
hexadecylfluorophosphonate (HDFP) (see note 1). 
6. DC Protein Assay Reagent (Bio-Rad). 
7. TBTA solution (1x): Prepare 83 mM Tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine 
ligand  (TBTA; Click Chemistry Tools) 50x stock solution (44.25 mg / mL) in DMSO. 
Store at -80 °C for long-term storage. Dilute the 50x stock solution in DMSO and t-
butanol following a 1:9:40 ratio respectively.  Store at room temperature for extended 
periods. 
8. TCEP solution: 50 mM stock solution (14.35 mg / mL) tris(2-carboxyethyl)phosphine 
(TCEP-HCl-Sigma) in DPBS and adjusted to pH 7 using concentrated base (NaOH or 
KOH). Prepare fresh for each use.  
9. Copper sulfate solution: 50 mM stock solution (7.98 mg / mL) Copper (II) sulfate 
anhydrous (CuSO4) solution in water. Store at room temperature for extended periods.  
10. Biotin-PEG3-azide solution: 10 mM stock (4.44 mg / mL) (Click Chemistry) in DMSO, 
and store at -80 °C. 
11. TAMRA-azide solution: 1 mM stock (0.63 mg / mL) (Click Chemistry Tools) in DMSO. 
Store at -80 °C. 
12. Resuspension buffer: 6 M Urea (360 mg / mL) and 2% w/v (20 mg / mL) sodium dodecyl 
sulfate (SDS), adjusting pH to 7 with HCl. Make fresh before use (see note 2). 
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13. Reducing solution: 200 mM (57.4 mg / mL) TCEP-HCl stock solution. Reconstitute with 
equimolar potassium hydroxide to neutralize HCl. Confirm with pH indicator strips. 
Make fresh before use.  
14. Alkylating solution: 400 mM (74.0 mg / mL) Iodoacetamide (Sigma) stock solution in 
water. Make fresh before use. Do not store in direct light. 
13. Hydroxylamine solution: 5 M (347 mg / mL) Hydroxylamine hydrochloride (Sigma), 
neutralized to pH 7 with concentrated NaOH or KOH. Make fresh before use. 
14. Chloroform (stored in light resistant bottle)  
15. Acetonitrile 
16.  Methanol. 
17. Streptavidin-agarose beads (Pierce). 
18. Wash buffer A: for streptavidin beads: DPBS with 2 M (120 mg / mL) Urea, 0.2% w / v 
(2 mg / mL) SDS 
19. Wash buffer B: 2 M urea in DPBS, pH 7. 
20. TMTsixplex Isobaric Label Reagent Set (Thermo Fisher) 
21. TEAB buffer: 50 mM triethylammonium bicarbonate (TEAB, from 1 M stock solution- 
Thermo Fisher) 
22. Mass spectrometry-grade Trypsin/Lys C (Promega). Reconstitute 20 µg in 100 µL 
resuspension buffer provided. 
23. Acetonitrile (MS grade) 
24. Equilibration solution: 0.1% Trifluoroacetic acid in Water (MS grade) 




This procedure performs optimally when carried out in a single day, without freeze-thaw steps. 
In order to minimize keratin contamination, work in a clean area and frequently change gloves 
throughout the procedure. Be sure to prepare a sufficient number of replicates (N = 3 or more) 
per condition for confident analysis. Here we describe a comparison between palmitic acid and 
17-ODYA treated cells. 
 
Metabolic cell labeling with 17-ODYA 
1. Grow cells to desired density in standard culture medium. Plan for at least 3 biological 
replicates per condition; depending on the cell type, 15 cm dishes should provide enough 
protein for 1 biological replicate.  
2. Wash cells gently with warm DPBS (37°C) and add ODYA Labeling Medium or 
Palmitic Acid Labeling Medium for the desired time. (see note 3). 
3. Wash cells three times with cold DPBS and harvesting using a cell scraper into a 1.5 mL 
microcentrifuge tube. 
4. Pellet cells by low speed centrifugation (500g) for 2 min at 4 °C. Aspirate DPBS and 
store the cell pellet at -80 °C (stable for several months). 
 
Preparation of cell lysates 
1. Add 0.5 – 1 mL Lysis Buffer per 15 cm plate of confluent cells in the pellet. Sonicate 
pellet on ice for 2 x 10 s.  
2. Transfer cell lysate to a thick-walled ultracentrifuge tube. Balance tube pairs and 
centrifuge for 45 minutes at 100,000g at 4 °C.  
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3. Carefully remove supernatant (S100) and add 0.5 mL lysis buffer to the pellet (P100). 
Sonicate the P100 sample 1 x 10 s. The S100 fraction can be saved or discarded since it is 
not used in the remaining purification (see Note 4). 
4. Quantify protein concentration using the Lowry assay (DC Protein Assay) or other 
equivalent method. Normalize each sample to 2 mg / mL protein using Lysis Buffer. 
Aliquot 50 µg of P100 lysate to a 1.5 mL microcentrifuge tube for later in-gel 
fluorescence analysis. 
5. Add 1 - 2 mg of the P100 sample in 1 mL of Lysis Buffer and split evenly across 2 x 1.5 
mL microcentrifuge tubes (0.5 mL each). 
6. Add 0.5 mL Methanol and 0.188 mL Chloroform and vortex. Centrifuge at max speed for 
10 minutes at 4 °C. Carefully remove the aqueous and organic layers to isolate the white 
protein layer. Add 0.5 mL cold methanol to each tube and briefly sonicate. Recombine 
the samples and centrifuge at 8000g for 5 min at 4 °C. Carefully aspirate methanol and 
add 1 mL DPBS. Sonicate to create a disperse precipitate (see Note 5). 
 
Click reaction for in-gel fluorescence 
1. Add 1 µL TAMRA-azide solution, 1 µL copper sulfate solution, and 3 µL TBTA solution 
to the 50 uL aliquot  of 1 mg / mL P100 lysate in DPBS that was set aside. Vortex and let 
sample sit for 30 minutes at room temperature. Vortex again and wait for another 30 
minutes.  
2. Add reducing 4X SDS sample loading buffer (supplemented with β-mercaptoethanol) to 
both samples. Avoid boiling to prevent thiol exchange or thioester hydrolysis. Analyze 
samples using standard SDS-PAGE. When the separation is complete, image the gel 
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using a laser scanning flatbed fluorescence imager to detect TAMRA fluorescence (with 
approximate excitation and emission wavelengths at 546 and 579 nm respectively).  
 
Click reaction and enrichment 
1. Using 1 – 1.5 mg of P100 lysate, add 58 µL of the Biotin-PEG3-azide solution, 23 µL of 
the TCEP solution, 23 µL of the copper sulfate solution, and 70 µL of the TBTA solution 
(see note 6). Rotate end over end for 1 hour at room temperature. 
2. Optional: For additional experimental controls for thioester-dependent labeling, to a 
separate series of replicates, add 1 M hydroxylamine (pH 7) and heat to 65 °C for 15 
minutes.  
3. Centrifuge the sample >8000g for 10 minutes at 4 °C. Decant and discard the 
supernatant. Add 0.5 mL cold DPBS, 0.5 mL cold methanol and sonicate a few seconds 
to disperse the protein pellet. Add 0.187 mL chloroform, vortex, and centrifuge >8000g 
for 10 minutes. Discard the aqueous and organic layers, saving the insoluble protein 
interface. Add 1 mL cold methanol, sonicate, and centrifuge 5 min at >8000g, and repeat. 
After decanting the residual methanol, add 0.5 mL Resuspension Buffer. Briefly vortex 
and sonicate if necessary to dissolve the protein pellet. 
4. Add 25 µL of the TCEP reducing solution (pH 7), vortex and leave at room temperature 
to react for 20 min. Then add 25 µL of the iodoacetamide alkylation solution, mix and 
leave at room temperature for 20 min in the dark. 
5. Quantify protein concentration using the Lowry assay (DC Protein Assay) or other 
equivalent method. Normalize each sample to a common protein concentration (see note 
7). 
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6. Transfer the sample to a 15 mL capped conical vial and dilute with 5 mL DPBS. Transfer 
75 µL streptavidin-agarose bead slurry to a fresh 15 mL conical vial and wash twice with 
Wash Buffer A. Add to sample and rotate end over end for 90 minutes. 
7. Place samples in a table top centrifuge and pellet beads at 500g for 3 minutes. Decant the 
supernatant. Add 10 mL of Wash Buffer A, turn vials upside down several times, and 
centrifuge at 500g for 3 minutes. Decant the supernatant and transfer beads in DBPS to 
individual Poly-prep chromatography columns.  
8. Attach each chromatography column to a multi-port vacuum manifold, and add 3 x 10 
mL of Wash Buffer 1, followed by 3 x 10 mL Wash Buffer B, each time allowing the 
buffer to nearly dry the column bed. Alternatively, the streptavidin beads can be 
sequentially washed with 4 cycles of centrifugation (500g x 3 min) in 10 mL Wash 
Buffer A and 4 cycles of centrifugation with 10 mL Wash Buffer B, carefully decanting 
the supernatant after each wash. 
 
Digestion and desalting 
1. Transfer beads to screw cap microcentrifuge tubes in Wash Buffer B. Carefully remove 
any residual Wash Buffer and add 100 µL TEAB Buffer, supplemented with 6 µL 
Trypsin/LysC solution. Shake at 225 rpm at 37 °C for at least 4 hours or overnight (see 
note 8). 
2. The next day, centrifuge samples at 500g for 1 minute. Transfer the supernatant to a new 
microcentrifuge tube. Wash the beads with an additional 50 µL TEAB buffer and 
centrifuge again. Collect and combine the supernatants.  
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3. Resuspend each TMT label reagent (0.2 mg) in 50 µL anhydrous acetonitrile and mix for 
5 minutes. (see note 9). Add 45 µL of each TMT label reagent to separate samples (i.e. 
palmitic acid control and 17-ODYA labeled; N = 3) and leave for 1 hour to incubate at 
room temperature.  
4. Add 1.2 µL of 5 M Hydroxylamine (pH 7) to each sample and wait for 15 minutes to 
allow reaction to quench. Add 1.5 µL of 50% Trifluoroacetic acid for a final 
concentration of about 0.8%. Combine labeled samples in one tube before desalting 
peptides.  
5. Desalt using an Oasis PRIME HLB µElution Plates (Waters), or equivalent solid phase 
extraction column. Condition resin with 200 µL acetonitrile, followed by 200 µL 
equilibration buffer. Load peptides onto the sorbent at low speed. Wash three times with 
400 µL equilibration buffer, followed by another three washes with 400 µL water to 
remove salts. Elute peptides with 75 µL of elution buffer (70% acetonitrile in water). Add 
an additional 75 µL elution buffer and pool the eluents. 
6. Dry the desalted elutions using a SpeedVac (Thermo) and store peptides at -80°C.  
7. Before mass spectrometry analysis, resuspend samples in MS-grade water containing 3% 
acetonitrile and 0.1% formic acid.  
8. Contact an appropriate mass spectrometry core facility or collaborator for mass 
spectrometry analysis, preferably using a quadrupole Orbitrap (Q-Exactive series) or 




1. HDFP is not commercially available, but can be substituted with other acyl 
fluorophosphonates, such as methyl arachidonyl fluorophosphonate. Hexadecylsulfonyl 
fluoride can also be used to block depalmitoylase activity.  
2. It is important to measure and neutralize the pH of all buffers, since basic conditions can 
promote thioester hydrolysis. Be aware, 6 M Urea can shift the solution to a more basic 
pH, which should be equilibrated to neutral pH before use. 
3. The labeling time for steady-state analysis typically requires 4 or more hours. Shorter 
time points can be used to measure differences in labeling rates between samples. Pulse-
chase experiments require sufficient time for probe metabolic incorporation (> 90 min) 
prior to addition of excess palmitic acid (chase). Different cell lines have different 
labeling kinetics, so it is important to use in-gel fluorescence analysis to confirm labeling 
conditions. Also, cells labeled with palmitic acid provide a control for non-specific 
enrichment from streptavidin beads.   
4. The S100 fraction has no detectable 17-ODYA labeling in-gel fluorescence analysis, and 
thus does not add any additional information to the mass spectrometry analysis. It is not 
essential to perform this fractionation step, but it concentrates the membrane proteome, 
removes soluble thioesterase enzymes, and limits nonspecific enrichment of common 
false positives. 
5. The initial chloroform / methanol precipitation is critical to increase reproducibility by 
removing excess, unincorporated probe prior to click chemistry conjugation. In addition, 
the efficiency of the click chemistry reaction is not affected when the protein is present as 
an insoluble slurry. 
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6. Typical click chemistry reactions for proteomics analysis use 100 µM biotin-azide. We 
find that increasing the biotin-azide concentration 5-fold significantly improves the 
reaction efficiency with alkynyl fatty acid conjugated proteins. We have not explored 
other commercially available copper ligands, which may further improve the reaction 
efficiency. 
7. Following click chemistry, the chloroform / methanol precipitation and methanol washes 
can lead to variable levels of protein loss. It is critical to include this additional protein 
normalization for TMT-based mass spectrometry quantitation. 
8. Agitation is used to maintain the bead slurry during digestion. The length of the digestion 
has not been thoroughly optimized, but longer incubations may affect thioester stability 
(which does not affect the analysis of tryptic peptides). 
9. The TMT reagents can be diluted several-fold and used over multiple separate 
experiments. Experiments should be designed to match experimental groups (N = 3) 
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